var title_f27_50_28448="Atopic dermatitis infantile II";
var content_f27_50_28448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis: infantile",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 328px; height: 447px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent erythema, mircovesiculation, papules, crust, and scale of a young Asian infant; the shoulders are relatively spared, being protected from scratching by clothing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, et al (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York, 1997. Copyright &copy; McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28448=[""].join("\n");
var outline_f27_50_28448=null;
var title_f27_50_28449="Parkinson disease treatment options — education, support, and therapy";
var content_f27_50_28449=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Parkinson disease treatment options ��������� education, support, and therapy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/50/28449/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28449/contributors\" id=\"au1659\">",
"       Daniel Tarsy, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/50/28449/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28449/contributors\" id=\"se6959\">",
"       Howard I Hurtig, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/50/28449/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28449/contributors\" id=\"de6967\">",
"       John F Dashe, MD, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/50/28449?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PARKINSON DISEASE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Parkinson disease (PD) is a chronic movement disorder that is best managed with a combination of close monitoring, medication, education, support and therapy, exercise, and nutrition. Surgery can be beneficial for some people with Parkinson disease.",
"    </p>",
"    <p>",
"     This topic will review education, support, exercise and physical therapy, and nutrition for Parkinson disease. The symptoms, diagnosis, and medical treatment of Parkinson disease are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=see_link\">",
"      \"Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/63/30708?source=see_link\">",
"      \"Patient information: Parkinson disease treatment options &mdash; medications (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PARKINSON DISEASE EDUCATION",
"     </span>",
"    </p>",
"    <p>",
"     Being diagnosed with a chronic disease can be a frightening experience, filled with uncertainty about what the future holds. This is especially true if the person knows a friend or family member who has experienced the disabling effects of Parkinson disease.",
"    </p>",
"    <p>",
"     In the first months and years after being diagnosed with Parkinson disease, it is important to gather information about initial symptoms and the treatment options that are available.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PARKINSON DISEASE SUPPORT",
"     </span>",
"    </p>",
"    <p>",
"     A person may respond to the diagnosis of Parkinson disease with anger, fear, depression, anxiety, resentment, or a combination of these emotions. Concerns about social and financial well being are common. Support groups can help the patient and family to interact with other individuals who have the same diagnosis to allow these people to share experiences and information. Support groups also provide opportunities to hear speakers talk about various aspects of Parkinson disease. Several national groups are listed below. (See",
"     <a class=\"local\" href=\"#H10\">",
"      'Where to get more information'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     People with young-onset Parkinson disease may benefit from a group composed of similar-aged patients. A handbook for young-onset patients is also available [",
"     <a class=\"abstract\" href=\"UTD.htm?27/50/28449/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Other types of support are available for people with Parkinson disease and their families, including psychologic, financial, legal, or occupational counseling. A physician, nurse, or social worker can usually provide contact information for these services in the local area.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      EXERCISE AND PHYSICAL THERAPY",
"     </span>",
"    </p>",
"    <p>",
"     It is not clear if exercise can slow the progression of Parkinson disease. However, it can help patients to feel better, both physically and mentally. Aerobic exercise may have a positive effect on disease status while improving quality of life and socialization. Favorable studies have appeared in the medical literature on exercises to improve balance, flexibility and strength (including dance and Tai Chi). However, these reports will need to be confirmed. Exercise can help to prevent some of the complications of Parkinson disease caused by rigidity and flexed (or bent) posture, such as shoulder, hip, and back pain. The benefits of exercise will persist as long as exercise continues. Many patients who participate in an exercise program feel more confident and gain a sense of control over their disease.",
"    </p>",
"    <p>",
"     Simple strengthening and stretching exercises are important for everyone with Parkinson disease. Aerobic exercises, such as walking (outdoors or on a treadmill, with support), riding a stationary bicycle, swimming, or water aerobics are easy to perform and usually energizing. A physical therapist can help you develop an exercise program that suits your needs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PARKINSON DISEASE SAFETY ISSUES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Falls prevention",
"     </span>",
"     &nbsp;&mdash;&nbsp;As Parkinson disease gets worse, the risk of falling increases. To reduce this risk, patients and caretakers are encouraged to make the home as safe as possible by:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Installing shower or tub grab-bars.",
"      </li>",
"      <li>",
"       Having adequate lighting in the house, especially at night. Use of light sensitive night lights or lamps on a timer may be helpful.",
"      </li>",
"      <li>",
"       Securing loose rugs, which can increase the risk of tripping.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The Centers for Disease Control and Prevention (CDC) has fall prevention materials available online (",
"     <a class=\"external\" href=\"file://www.cdc.gov/ncipc/duip/preventadultfalls.htm\">",
"      www.cdc.gov/ncipc/duip/preventadultfalls.htm",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Driving safety",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with Parkinson disease can continue to drive as long as their motor symptoms remain mild. Driving ability must be monitored and formally re-evaluated if and when motor and cognitive symptoms worsen. The Association of Driver Rehabilitation Specialists (1-877-529-1830 in the US and Canada) can provide names of local occupational therapists or driving specialists who can perform driving tests to see if Parkinson disease is affecting driving.",
"    </p>",
"    <p>",
"     If it is necessary to stop or cut back on driving, other forms of transportation are available, such as taxi cabs, shuttle buses, public buses, or trains. Walking, if practical, is always a healthy way to get around. The ElderCare Locator (",
"     <a class=\"external\" href=\"file://www.eldercare.gov/\">",
"      www.eldercare.gov",
"     </a>",
"     ) is a resource that can provide assistance in locating help with transportation as well as housing, financial or legal services, health insurance, and long-term care.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      PARKINSON DISEASE SPEECH THERAPY",
"     </span>",
"    </p>",
"    <p>",
"     Problems with speech, including slurred speech and speaking too quietly, are common in people with Parkinson disease. These problems develop as muscles weaken in the voice box, throat, mouth, tongue, and lips.",
"    </p>",
"    <p>",
"     A voice or speech therapist can help overcome speech problems. This may involve training to speak more loudly and clearly, conserving energy when speaking (speaking only important",
"     <span class=\"nowrap\">",
"      words/phrases),",
"     </span>",
"     and using nonverbal methods such as a letter or word board, hand signals.",
"    </p>",
"    <p>",
"     A speech therapist can also evaluate and treat difficulties with swallowing. The medical term for this problem is dysphagia. Dysphagia can increase the risk of coughing, choking, or inhaling food (aspiration), which can lead to pneumonia. Treatments for dysphagia may include sitting up straight while eating, tilting the head slightly forward, eating small bites and chewing completely, and not speaking while eating. Another treatment is the use of a powder to thicken liquids or thin food, making them easier to swallow.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      PARKINSON DISEASE NUTRITION",
"     </span>",
"    </p>",
"    <p>",
"     There is no specific diet recommended for people with Parkinson disease. However, some patients notice that protein in a meal can block the effect of a dose of levodopa taken around meal time. People who notice this effect should speak to their healthcare provider.",
"    </p>",
"    <p>",
"     It is important to be sure that the person is getting an adequate number of calories and nutrients to maintain strength, bone structure, and muscle mass. Problems with unintended weight loss, poor appetite, eating and swallowing, or preparing food should be discussed with a healthcare provider. The provider may recommend meeting with a registered dietitian.",
"    </p>",
"    <p>",
"     Constipation is a frequent problem for people with Parkinson disease because of disease-related changes in the bowels or as a side effect of Parkinson disease medications. Constipation can sometimes be managed with changes in diet or use of a laxative or stool softener. A full discussion of treatments for constipation is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      \"Patient information: Constipation in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498777425\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11171369\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=see_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/8/34947?source=see_link\">",
"      Patient information: Medicines for Parkinson disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/14/13538?source=see_link\">",
"      Patient information: Tremor (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11171377\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=see_link\">",
"      Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/63/30708?source=see_link\">",
"      Patient information: Parkinson disease treatment options &mdash; medications (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15943?source=see_link\">",
"      Bradykinetic movement disorders in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36970?source=see_link\">",
"      Etiology and pathogenesis of Parkinson disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21784?source=see_link\">",
"      Management of comorbid problems associated with Parkinson disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18857?source=see_link\">",
"      Motor fluctuations and dyskinesia in Parkinson disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15863?source=see_link\">",
"      Neuroprotective therapy for Parkinson disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4277?source=see_link\">",
"      Nonpharmacologic management of Parkinson disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link\">",
"      Overview of tremor",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=see_link\">",
"      Parkinson disease dementia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link\">",
"      Surgical treatment of Parkinson disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        MedlinePlus",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://www.parkinson.org/\">",
"        National Parkinson Foundation",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm\">",
"        National Institute of Neurological Disorders and Stroke",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://www.pdf.org/\">",
"        Parkinson's Disease Foundation",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://www.wemove.org/\">",
"        We Move",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/50/28449?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Young Parkinson's Handbook, Mark MH, Sage JI (Eds), The American Parkinson Disease Association, Inc, New York 2000. www.stlapda.org/content/pdfs/Young%20Parkinson%20Handbook.pdf (Accessed on February 14, 2012).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_50_28449=[""].join("\n");
var outline_f27_50_28449=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PARKINSON DISEASE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PARKINSON DISEASE EDUCATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PARKINSON DISEASE SUPPORT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           EXERCISE AND PHYSICAL THERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PARKINSON DISEASE SAFETY ISSUES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           PARKINSON DISEASE SPEECH THERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           PARKINSON DISEASE NUTRITION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_50_28450="Shortness of breath (dyspnea)";
var content_f27_50_28450=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/50/28450/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28450/contributors\" id=\"au5753\">",
"       Richard M Schwartzstein, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/50/28450/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28450/contributors\" id=\"se5969\">",
"       James K Stoller, MS, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/50/28450/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28450/contributors\" id=\"de1810\">",
"       Helen Hollingsworth, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28450/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/50/28450?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SHORTNESS OF BREATH OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Feeling short of breath can be an uncomfortable or frightening experience, especially if it has never happened to you before. It can be caused by problems with the lungs or with the heart, or by a low blood count, but its specific cause can sometimes take a while to pinpoint. Luckily, most causes of shortness of breath can be treated quickly once the cause is identified.",
"    </p>",
"    <p>",
"     Many cases of shortness of breath are caused by simple, short lived problems, such as respiratory tract infections or allergies. The medical term for shortness of breath is dyspnea.",
"    </p>",
"    <p>",
"     This article will discuss the main causes of shortness of breath and tests that might be used. More information about shortness of breath is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"      \"Approach to the patient with dyspnea\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CAUSES OF SHORTNESS OF BREATH",
"     </span>",
"    </p>",
"    <p>",
"     Acute shortness of breath, which comes on suddenly, over the course of minutes or hours, usually has different causes than chronic shortness of breath, which develops over weeks or months.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Acute shortness of breath",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acute shortness of breath usually happens along with other symptoms. The most common causes of acute shortness of breath include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Respiratory tract infections, such as pneumonia. These infections usually cause other symptoms, such as fever, cough, or coughing up sputum or mucus. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"        \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       A severe allergic reaction (anaphylaxis), which usually also causes itching, swelling, a rash, or other symptoms. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"        \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Asthma, which often causes wheezing. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"        \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=see_link\">",
"        \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       A blockage in the respiratory tract, which could happen after accidentally inhaling a foreign object, such as a peanut or partially chewed meat.",
"      </li>",
"      <li>",
"       A blood clot or other blockage in an artery in the lungs. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"        \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       A collapsed lung (pneumothorax). (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link\">",
"        \"Primary spontaneous pneumothorax in adults\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Interruptions in blood flow to the heart muscle, which might happen during a heart attack. When this is the cause of shortness of breath, there are often other symptoms, such as pain or pressure in the chest. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"        \"Patient information: Heart attack (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Heart failure, a condition that affects the heart's ability to pump blood throughout the body. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"        \"Patient information: Heart failure (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Pregnancy changes a woman's circulatory and respiratory systems, even before the woman is visibly pregnant. This type of shortness of breath is a normal change that happens during pregnancy. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39446?source=see_link\">",
"        \"Dyspnea during pregnancy\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Chronic shortness of breath",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some of the same things that cause acute shortness of breath can also cause chronic shortness of breath. For example, asthma symptoms can come and go over months or years. Heart failure can also continue to cause shortness of breath over months or years.",
"    </p>",
"    <p>",
"     The most common causes of chronic shortness of breath include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Asthma. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"        \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=see_link\">",
"        \"Patient information: Asthma treatment in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Chronic obstructive pulmonary disease, a lung condition that often affects current or former smokers, includes conditions such as emphysema and chronic bronchitis. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"        \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Interstitial lung disease, a collection of lung disorders that involve damage or scarring of lung tissue. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"        \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Cardiomyopathy, a heart condition that leads to changes in the heart's shape and size, and ability to pump blood to the rest of the body. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=see_link\">",
"        \"Patient information: Dilated cardiomyopathy (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"        \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Deconditioning, the technical term for being out of shape. For example, if you do not exercise regularly, you may develop shortness of breath when climbing stairs.",
"      </li>",
"      <li>",
"       Obesity can cause shortness of breath as extra weight in the chest and abdomen presses on the lungs.",
"      </li>",
"      <li>",
"       Pulmonary hypertension, which is high blood pressure in the arteries to your lungs. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"        \"Overview of pulmonary hypertension in adults\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      SHORTNESS OF BREATH SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     People describe shortness of breath in different ways. Some people say they feel \"hungry for air,\" others say they feel as though they \"cannot breathe deeply enough.\"",
"    </p>",
"    <p>",
"     These descriptions hold important clues about the possible cause of the problem. Here is a questionnaire your healthcare provider may ask you to complete to get a better sense of your symptoms (",
"     <a class=\"graphic graphic_table graphicRef57712 \" href=\"UTD.htm?25/45/26331\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Anyone who develops shortness of breath, particularly if it occurs or persists while at rest, should see a healthcare provider. If you have severe shortness of breath or also have chest pain or nausea, go to the closest emergency room. Shortness of breath is not a symptom to ignore.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      SHORTNESS OF BREATH DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider can learn a lot about your condition by listening to your description of the problem, and by asking about any other symptoms you may have. He or she can also learn a lot by listening to your heart and lungs with a stethoscope, and by checking your legs for swelling.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Your healthcare provider may also order one or more of the following tests to help diagnose the problem:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A blood test called a hematocrit can check for anemia, a condition that affects the blood's ability to carry oxygen.",
"      </li>",
"      <li>",
"       A blood test called a BNP can indicate if you have fluid buildup in your lungs.",
"      </li>",
"      <li>",
"       A chest x-ray to look for pneumonia, or lung inflammation or scarring.",
"      </li>",
"      <li>",
"       An EKG is a test of your heart muscle that looks for signs of a heart attack.",
"      </li>",
"      <li>",
"       Spirometry measures the amount of air your lungs can hold and how effectively your lungs can empty and fill with air. This test can also indicate if you have asthma or emphysema.",
"      </li>",
"      <li>",
"       Oximetry measures the amount of oxygen in your blood.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      SHORTNESS OF BREATH TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment for your shortness of breath will depend a lot on what is causing it. Shortness of breath caused by asthma, for example, will need one type of treatment, whereas shortness of breath caused by heart failure will need quite another.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498601376\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29457217\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/30/40418?source=see_link\">",
"      Patient information: Pneumothorax (collapsed lung) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/50/10018?source=see_link\">",
"      Patient information: Pleural effusion (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=see_link\">",
"      Patient information: Sick sinus syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/31/7666?source=see_link\">",
"      Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/1/32785?source=see_link\">",
"      Patient information: Atelectasis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/31/41457?source=see_link\">",
"      Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/15/33010?source=see_link\">",
"      Patient information: Pleural mesothelioma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13956?source=see_link\">",
"      Patient information: Diastolic heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7684?source=see_link\">",
"      Patient information: Systolic heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=see_link\">",
"      Patient information: Interstitial lung disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19603?source=see_link\">",
"      Patient information: Lung transplant (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29457232\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/60/18374?source=see_link\">",
"      Patient information: Asthma treatment in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=see_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39446?source=see_link\">",
"      Dyspnea during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28938?source=see_link\">",
"      Evaluation of the adult with dyspnea in the emergency department",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8839?source=see_link\">",
"      Physiology of dyspnea",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/003075.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/003075.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Chest Physicians",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.chestnet.org/downloads/patients/guides/ShortnessofBreath.pdf\">",
"      www.chestnet.org/downloads/patients/guides/ShortnessofBreath.pdf",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?27/50/28450/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 22, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/50/28450?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28450/abstract/1\">",
"      Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999; 159:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28450/abstract/2\">",
"      Han J, Zhu Y, Li S, et al. The language of medically unexplained dyspnea. Chest 2008; 133:961.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_50_28450=[""].join("\n");
var outline_f27_50_28450=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SHORTNESS OF BREATH OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CAUSES OF SHORTNESS OF BREATH",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           SHORTNESS OF BREATH SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           SHORTNESS OF BREATH DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           SHORTNESS OF BREATH TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?25/45/26331\" title=\"table 1\">",
"           Dyspnea questionnaire PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_50_28451="Traction-countertraction for shoulder reduction";
var content_f27_50_28451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Traction-countertraction for reduction of anterior shoulder dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note how the clinician on the left has the sheet wrapped around him, allowing him to use his body weight to create traction. Some clinicians employ gentle external rotation to the affected arm while providing traction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott C Sherman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28451=[""].join("\n");
var outline_f27_50_28451=null;
var title_f27_50_28452="Suprasternal color of Doppler TOF";
var content_f27_50_28452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1042px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PEDS/51331/Supra_color_Dopp_TOF.mp4?title=Suprasternal+color+of+Doppler+TOF\" style=\"width:432px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Suprasternal notch short axis view with color flow mapping in tetralogy of Fallot (TOF)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This still frame from the accompanying echocardiographic video clip of the suprasternal notch short axis view in a patient with tetralogy of Fallot (TOF) highlights the flow in the right (RPA) and left pulmonary arteries (LPA). These vessels are without evidence of proximal stenosis.",
"    <div class=\"footnotes\">",
"     Ao: ascending aorta.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28452=[""].join("\n");
var outline_f27_50_28452=null;
var title_f27_50_28453="Herpes zoster ophthalmicus";
var content_f27_50_28453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes zoster ophthalmicus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lesions of herpes zoster progress through stages, beginning as red macules and papules that, in the course of seven to ten days, evolve into vesicles and form pustules and crusts (scabs). A common site is the distribution of the opthalmic division of the trigeminal nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sampathkumar, P, Drage, LA, Martin, DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009; 84:274. Copyright &copy; 2009 Quadrant HealthCom, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28453=[""].join("\n");
var outline_f27_50_28453=null;
var title_f27_50_28454="Treatment of small intestinal bacterial overgrowth";
var content_f27_50_28454=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of small intestinal bacterial overgrowth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28454/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28454/contributors\">",
"     Jon A Vanderhoof, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28454/contributors\">",
"     Rosemary J Pauley-Hunter, NP-C, MS, RN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28454/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28454/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28454/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28454/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/50/28454/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small intestinal bacterial overgrowth (SIBO) is a condition due to excessive colonization of the small intestine by bacteria (most commonly coliform bacteria). It can be associated with mucosal inflammation and nutrient malabsorption. Affected patients may be asymptomatic or have one or more symptoms including bloating, abdominal discomfort, diarrhea, dyspepsia, and in severe cases weight loss.",
"   </p>",
"   <p>",
"    This topic review will discuss the treatment of SIBO. The etiology, pathogenesis, clinical manifestations, and diagnosis of SIBO are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2136?source=see_link\">",
"     \"Etiology and pathogenesis of small intestinal bacterial overgrowth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=see_link\">",
"     \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130992248\">",
"    <span class=\"h1\">",
"     TREATMENT OF SMALL INTESTINAL BACTERIAL OVERGROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment of small intestinal bacterial overgrowth (SIBO) is antibiotic therapy. The underlying disease should be treated, when possible. Dietary manipulation may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Treatment of the underlying disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying cause of SIBO may be small intestinal stasis due to anatomic abnormalities (eg, diverticulosis, surgical blind loops or strictures), abnormal small intestinal motility (eg, drug-induced dysmotility, diabetes), abnormal communication between the proximal and distal intestine (eg, fistula), or may be multifactorial in etiology (eg, hypochlorhydria, chronic pancreatitis, associated with irritable bowel syndrome) (",
"    <a class=\"graphic graphic_table graphicRef81285 \" href=\"UTD.htm?9/2/9260\">",
"     table 1",
"    </a>",
"    ). These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2136?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology and pathogenesis of small intestinal bacterial overgrowth\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsurgical conditions associated with intestinal stasis should be corrected when possible. This includes the elimination or substitution of drugs known to decrease intestinal motility (eg, narcotics, benzodiazepines).",
"     </li>",
"     <li>",
"      In cases of sluggish motility, such as chronic intestinal pseudo-obstruction, methods to enhance motility can be attempted. Prokinetic agents including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"       domperidone",
"      </a>",
"      , cisapride,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/4/4164?source=see_link\">",
"       tegaserod",
"      </a>",
"      may also have benefit but large studies are lacking [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/1\">",
"       1",
"      </a>",
"      ]. Prokinetics may be a useful adjunct for SIBO in patients who do not respond to or are intolerant of antibiotics, provided that they have documented dysmotility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=see_link&amp;anchor=H83057808#H83057808\">",
"       \"Chronic intestinal pseudo-obstruction\", section on 'Motility assessment'",
"      </a>",
"      .) A short two-week trial of erythromycin (30 to 50",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum 2 grams daily) will quickly demonstrate any beneficial effects on motility and will eliminate excess bacterial colonies.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       Octreotide",
"      </a>",
"      induces phase III of the migrating motor complex that causes a propagating peristaltic wave through the small intestine. A pilot study in five patients with intestinal scleroderma and SIBO found improved symptoms and reduced breath hydrogen excretion after the administration of low doses of octreotide (50 micrograms) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/2\">",
"       2",
"      </a>",
"      ]. However, additional studies are needed to confirm these findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies have suggested that prolonged or excessive acid suppression may be a contributing factor for the development of symptoms associated with bacterial overgrowth, although these results have been conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. In situations where a proton pump inhibitor (PPI) is a suspected contributor to bacterial overgrowth, lifestyle measures for treatment of gastroesophageal reflux disease (GERD) or a reduction in acid suppression to the lowest possible dose for the condition being treated and shortest duration may be beneficial in alleviating symptoms of overgrowth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the case of iatrogenic surgical causes of SIBO and for fistulae between the proximal and distal intestine, surgery may be necessary in patients who fail to respond to dietary manipulation and antibiotics and have significant weight loss and diarrhea.",
"      <br/>",
"      <br/>",
"      Intestinal transplant may restore function in patients with intestinal failure due to short bowel syndrome and other causes but is associated with a high risk of rejection and subsequent sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=see_link&amp;anchor=H21#H21\">",
"       \"Management of the short bowel syndrome in adults\", section on 'Nontransplantation procedures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dietary manipulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary manipulation may assist in the treatment of SIBO. The primary goal is to provide a diet that consists of nutrients readily absorbed thus leaving fewer calories for bacterial metabolism. As carbohydrates are the primary nutritional source for bacteria, diets should be modified to reduce nonabsorbed carbohydrates. A high fat, low carbohydrate, low fiber diet is helpful, as fat is not significantly metabolized by the bacteria and supplies a good calorie source in those requiring supplemental nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/11\">",
"     11",
"    </a>",
"    ]. The substitution of fat for carbohydrates may also lessen the development of D-lactic acidosis, the production of small bowel gas, bloating, and discomfort. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=see_link\">",
"     \"D-Lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    deficiency develops in many adult patients with SIBO, lactose-containing foods should be avoided in patients with a positive breath test for lactose intolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nutritional support is important for all patients with SIBO, particularly those who have significant weight loss or evidence of micronutrient deficiency. Deficiencies of calcium, magnesium, iron, vitamin B12, and fat soluble vitamins including vitamin D are infrequent but may be more subtle signs of overgrowth and need to be tested for and corrected when present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with SIBO require treatment with antibiotics. The goal of therapy is to reduce (rather than eradicate) the flora, leading to symptomatic improvement. Recommended antibiotic regimens reflect the predominant organisms associated with SIBO and cover both aerobic and anaerobic enteric bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/12\">",
"     12",
"    </a>",
"    ]. Bacterial culture with sensitivity testing is not helpful since various bacterial species with different antibiotic sensitivities coexist. In addition, many bacterial species in the gut cannot be grown in culture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=see_link\">",
"     \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few randomized control trials of antibiotics to treat bacterial overgrowth and the evidence for use of specific antibiotics is largely from observational studies. Adequate antimicrobial coverage can be achieved with a 7- to 10-day course of the following: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       Rifaximin",
"      </a>",
"      (1650",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      a nonabsorbable antibiotic, may be the antibiotic of choice as clinical resistance may be less frequent than with other antibiotics (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. In a randomized controlled trial in which 142 patients with SIBO were randomized to seven days of rifaximin (1200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (750",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      glucose breath test normalization rates at one month were significantly higher in patients treated with rifaximin compared with metronidazole (63.4 versus 43.7 percent).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/17\">",
"       17",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      combined with a cephalosporin (30",
"      <span class=\"nowrap\">",
"       mg/kg/day),",
"      </span>",
"      such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (10 to 12",
"      <span class=\"nowrap\">",
"       mg/kg/day),",
"      </span>",
"      or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg/day).",
"      </span>",
"      If gentamicin is used on a continuous basis, random drug levels should be obtained intermittently to assess for any toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/13,18,19\">",
"       13,18,19",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       Norfloxacin",
"      </a>",
"      (800",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Traditionally,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    250 mg four times daily by mouth was considered effective. However, because of trends in microbial resistance, many patients do not respond adequately to monotherapy with this drug. In addition, tetracycline is contraindicated in children younger than eight years.",
"   </p>",
"   <p>",
"    Regardless of which antibiotic is used, a single course of therapy for 7 to 10 days may improve symptoms and have an effect lasting for months. However, some patients require prolonged therapy (eg, one to two months) before a response is seen. It is usually unnecessary to repeat breath testing if symptoms of abdominal pain, diarrhea, bloating, and flatulence respond to treatment.",
"   </p>",
"   <p>",
"    Recurrence is common after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/20\">",
"     20",
"    </a>",
"    ]. In a study involving 80 patients with SIBO who were treated successfully with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    , recurrence rates were 13, 28, and 44 percent after three, six, and nine months, respectively. Recurrence was more likely in older adults, those with a history of an appendectomy, and with chronic PPI use. Most cases were heralded by a recurrence of abdominal pain, bloating, flatulence, and diarrhea.",
"   </p>",
"   <p>",
"    There are no controlled trials to guide the duration of treatment or management of recurrent SIBO and recommendations are based on clinical experience. Successful treatment of recurrence with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/21\">",
"     21",
"    </a>",
"    ]; other antibiotic regimens are likely to be efficacious as well. Patients with recurrent symptoms require repeated courses of therapy and others need treatment on a regular basis (such as the first 5 to 10 days out of every month or every other week). In the latter patients, rotating antibiotic regimens may help to prevent the development of resistance. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H644412424\">",
"    <span class=\"h2\">",
"     Probiotics, prebiotics, and synbiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics are defined as live microorganisms, which when administered in adequate amounts confer a health benefit on the host [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/22\">",
"     22",
"    </a>",
"    ]. At present, there is conflicting evidence in support of probiotics in the treatment of SIBO and therefore probiotics are not recommended at the present time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/11,23\">",
"     11,23",
"    </a>",
"    ]. One study in children with bacterial overgrowth associated with short bowel syndrome suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    <em>",
"     plantarum",
"    </em>",
"    299v may either prevent or delay symptom recurrence after antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/11\">",
"     11",
"    </a>",
"    ]. In a randomized double-blind trial among 12 patients with bacterial overgrowth-related chronic diarrhea, both",
"    <em>",
"     Lactobacillus casei",
"    </em>",
"    and",
"    <em>",
"     Lactobacillus acidophilus",
"    </em>",
"    strains proved effective in reducing the mean number of stools at 15 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/24\">",
"     24",
"    </a>",
"    ]. However, in another double-blind crossover study,",
"    <em>",
"     Lactobacillus",
"    </em>",
"    <em>",
"     fermentum KLD",
"    </em>",
"    showed no benefit over placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prebiotics are defined as nondigestible but fermentable foods that beneficially affect the host by selectively stimulating the growth and activity of one or a limited number of bacterial species in the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/25\">",
"     25",
"    </a>",
"    ]. Prebiotics stimulate the preferential growth of a limited number of health-promoting commensal flora, especially, but not exclusively, lactobacilli and bifidobacteria. Evidence for efficacy of prebiotics, whether administered alone or in conjunction with a probiotic (a combination referred to as a synbiotic), is limited and there are no data on their use in SIBO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT OF INFLAMMATION SECONDARY TO SIBO",
"    </span>",
"    &nbsp;&mdash;&nbsp;In more severe cases of small intestinal bacterial overgrowth (SIBO), colitis and ileitis can occur, which can mimic a flare of Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In addition, the enteritis can elicit an inflammatory cascade with resultant inflammatory arthritis. A diagnosis of SIBO should therefore be considered in patients with Crohn&rsquo;s disease that appear have an acute flare. In addition, if patients with SIBO have unexplained anemia or occult blood loss, we suggest an evaluation for enteritis with an upper GI series with small bowel follow through, computed tomography (CT)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    magnetic resonance (MR) enterography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colonoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689169#H12689169\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Imaging studies'",
"    </a>",
"    .) Mild to moderate enteritis associated in the subset of patients with short bowel syndrome associated SIBO delays weaning of parenteral nutrition and may require treatment with antiinflammatory therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    or corticosteroids when severe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28454/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small intestinal bacterial overgrowth (SIBO) is a condition due to excessive colonization of the small intestine by bacteria (most commonly coliform bacteria). It may be associated with mucosal inflammation and nutrient malabsorption. Affected patients may be asymptomatic or have one or more symptoms including bloating, abdominal discomfort, diarrhea, dyspepsia, and in severe cases weight loss. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of small intestinal bacterial overgrowth (SIBO) consists of treatment of the underlying disease, dietary manipulation, and antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SIBO due to sluggish motility should be treated with medications to enhance motility to eliminate and prevent relapse of SIBO. Drugs that reduce motility (narcotics, benzodiazepines, antimotility agents) should be discontinued.",
"      <br/>",
"      <br/>",
"      As prolonged or excessive acid suppression may be a contributing factor for the development of symptoms of SIBO, the use of acid suppressive medication should be minimized. Lifestyle measures should be considered for treatment of gastroesophageal reflux disease (GERD) and acid suppressive medication should be prescribed at the lowest possible dose for the condition being treated and for the shortest duration.",
"      <br/>",
"      <br/>",
"      In the case of iatrogenic surgical causes of SIBO and fistulae between the proximal and distal intestine, surgery may be necessary in patients with significant weight loss and malabsorption. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment of the underlying disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A diet consisting of high fat, low carbohydrate, and low fiber may reduce symptoms. As",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"       lactase",
"      </a>",
"      deficiency develops in many adult patients with SIBO, lactose-containing foods should be avoided. Additional nutritional support and correction of micronutrient deficiency may be required in patients with significant malabsorption. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dietary manipulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest antibiotic treatment for SIBO with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       rifaximin",
"      </a>",
"      (1650",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 7 to 10 days) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Adequate antimicrobial coverage can also be achieved with other antibiotic combinations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrence is common after treatment. Patients with recurrent symptoms may require repeated courses of therapy and others need treatment on a regular basis (such as the first 5 to 10 days out of every month or every other week). In the latter patients, rotating antibiotic regimens may help to prevent the development of resistance. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe cases of small intestinal bacterial overgrowth (SIBO) may result in colitis and ileitis, which can mimic a flare of Crohn's disease. An evaluation for enteritis should be performed in patients with SIBO with anemia or occult blood loss. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment of inflammation secondary to SIBO'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/1\">",
"      Parodi A, Sessarego M, Greco A, et al. Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. Am J Gastroenterol 2008; 103:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/2\">",
"      Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/3\">",
"      Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011; 41:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/4\">",
"      Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/5\">",
"      Law D, Pimentel M. Proton pump inhibitor therapy does not affect hydrogen production on lactulose breath test in subjects with IBS. Dig Dis Sci 2010; 55:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/6\">",
"      Hutchinson S, Logan R. The effect of long-term omeprazole on the glucose-hydrogen breath test in elderly patients. Age Ageing 1997; 26:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/7\">",
"      Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/8\">",
"      Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994; 35:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/9\">",
"      Ratuapli SK, Ellington TG, O'Neill MT, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol 2012; 107:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/10\">",
"      Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 2003; 124:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/11\">",
"      Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/12\">",
"      Singh VV, Toskes PP. Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment. Curr Treat Options Gastroenterol 2004; 7:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/13\">",
"      Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin North Am 2010; 24:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/14\">",
"      Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 22:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/15\">",
"      Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007; 25:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/16\">",
"      Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008; 53:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/17\">",
"      Attar A, Flouri&eacute; B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999; 117:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/18\">",
"      Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999; 94:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/19\">",
"      Malik BA, Xie YY, Wine E, Huynh HQ. Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure. Can J Gastroenterol 2011; 25:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/20\">",
"      Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008; 103:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/21\">",
"      Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci 2011; 56:2067.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Agriculture Organization of the United Nations. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. file://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf (Accessed on July 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/23\">",
"      Stotzer PO, Blomberg L, Conway PL, et al. Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD. Scand J Infect Dis 1996; 28:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/24\">",
"      Gaon D, Garmendia C, Murrielo NO, et al. Effect of Lactobacillus strains (L. casei and L. Acidophillus Strains cerela) on bacterial overgrowth-related chronic diarrhea. Medicina (B Aires) 2002; 62:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/25\">",
"      Scientific concepts of functional foods in Europe. Consensus document. Br J Nutr 1999; 81 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/26\">",
"      Taylor SF, Sondheimer JM, Sokol RJ, et al. Noninfectious colitis associated with short gut syndrome in infants. J Pediatr 1991; 119:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28454/abstract/27\">",
"      Klaus J, Spaniol U, Adler G, et al. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease. BMC Gastroenterol 2009; 9:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4778 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28454=[""].join("\n");
var outline_f27_50_28454=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130992248\">",
"      TREATMENT OF SMALL INTESTINAL BACTERIAL OVERGROWTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Treatment of the underlying disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dietary manipulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H644412424\">",
"      Probiotics, prebiotics, and synbiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT OF INFLAMMATION SECONDARY TO SIBO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4778\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4778|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/2/9260\" title=\"table 1\">",
"      Disorders associated with bacterial overgrowth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=related_link\">",
"      Chronic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=related_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=related_link\">",
"      D-Lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2136?source=related_link\">",
"      Etiology and pathogenesis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=related_link\">",
"      Management of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_50_28455="Traumatic causes of acute knee pain and injury in the young athlete";
var content_f27_50_28455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Traumatic causes of acute knee pain and injury in the young athlete",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28455/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28455/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28455/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28455/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28455/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28455/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/50/28455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute knee pain following trauma in the young athlete may result from internal derangement, musculotendinous strains,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    contusions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/1\">",
"     1",
"    </a>",
"    ]. Internal derangement is a nonspecific term that encompasses fractures, chondral lesions, and injuries to the ligaments or menisci. Clinical clues to internal derangement include the inability to bear weight within a few minutes of injury, and knee swelling or hemarthrosis within 24 hours of the injury. Knee dislocation is a rare but limb threatening injury that should be suspected in patients with significant knee instability, deformity or visible malalignment after high-velocity trauma (eg, motor vehicle collision, skiing injury) or contact sport, though fractures can mimic dislocation as well.",
"   </p>",
"   <p>",
"    Acute knee pain also can be caused by primary pathology in the hip, such as arthritis, osteomyelitis, slipped capital femoral epiphysis (SCFE), and Legg-Calv&eacute;-Perthes disease.",
"   </p>",
"   <p>",
"    The common causes of acute knee pain in the young athlete will be reviewed here. The causes of chronic knee pain and the evaluation and management of acute knee pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8726?source=see_link\">",
"     \"Causes of chronic knee pain in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of acute knee pain in the young athlete include superficial contusions and injuries to the bones, ligaments, menisci, tendons,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    muscles (",
"    <a class=\"graphic graphic_table graphicRef67811 \" href=\"UTD.htm?10/46/10987\">",
"     table 1",
"    </a>",
"    ). Referred or direct pain from the hip or underlying malignancy, infection, inflammatory disease, or bleeding disorder is also an important consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8889118\">",
"    <span class=\"h2\">",
"     Fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the physes (growth plates) of the distal femur and proximal tibia are important causes of knee pain in the young athlete. Patients with these fractures typically have pain, swelling,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deformity at the site of injury and are unable to walk. These injuries are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42807?source=see_link\">",
"     \"Proximal tibial fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/5/7257?source=see_link\">",
"     \"Distal femoral fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ligament injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute knee trauma may result in ligamentous injuries, which may occur in isolation or in conjunction with other ligamentous, bone, or meniscal injuries. More significant injuries involve greater number of structures, have a greater extent of area damage and have greater risk for neurovascular damage. Tibiofemoral dislocation is the most serious of the multiple structure injuries because it is likely associated with popliteal artery and peroneal nerve damage.",
"   </p>",
"   <p>",
"    Ligamentous injuries (sprains) are manifest by pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laxity of the ligaments. The grading and evaluation of ligamentous injuries are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Knee dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dislocations of the tibiofemoral joint of the knee are potentially limb-threatening injuries that require emergent reduction followed by careful neurovascular assessment (",
"    <a class=\"graphic graphic_algorithm graphicRef72754 \" href=\"UTD.htm?24/46/25327\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38038?source=see_link&amp;anchor=H4#H4\">",
"     \"Knee (tibiofemoral) dislocation and reduction\", section on 'Procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Knee dislocations result from the rupture of at least two, but usually three, of the four major ligaments, resulting in multidirectional instability. The anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL) usually are involved, although this is not always the case. Knee dislocations are most common after high-velocity trauma (eg, motor vehicle accident or fall from height), but can occur with low-velocity trauma in contact sports. Mechanisms of injury include hyperextension, valgus rotary stress, and varus rotary stress. Most knee dislocations are anterior or posterior, with the direction of dislocation indicating the movement of the tibia relative to the femur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38038?source=see_link&amp;anchor=H3#H3\">",
"     \"Knee (tibiofemoral) dislocation and reduction\", section on 'Mechanism and presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Knee dislocations usually are obvious when there is gross deformity of the knee, but dislocations that have reduced spontaneously may be more subtle. Thus, whenever it is clear from the initial evaluation that two ligaments have ruptured (the",
"    <span class=\"nowrap\">",
"     ACL/medial",
"    </span>",
"    collateral ligament [MCL] combination is most common), the possibility of a spontaneously reduced knee dislocation must be considered and the neurovascular status of the lower extremity carefully monitored. Complications of knee dislocation include popliteal artery and peroneal nerve injury, which occur primarily after anterior-posterior and lateral dislocations, respectively (",
"    <a class=\"graphic graphic_figure graphicRef50856 \" href=\"UTD.htm?15/9/15510\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38038?source=see_link&amp;anchor=H3#H3\">",
"     \"Knee (tibiofemoral) dislocation and reduction\", section on 'Mechanism and presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38038?source=see_link&amp;anchor=H8#H8\">",
"     \"Knee (tibiofemoral) dislocation and reduction\", section on 'Postreduction management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38038?source=see_link&amp;anchor=H11#H11\">",
"     \"Knee (tibiofemoral) dislocation and reduction\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Anterior cruciate ligament",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and prevalence of ACL injuries among skeletally immature athletes are unknown. However, ACL injuries have increased as greater numbers of children and adolescents participate in community sports programs, including skiing, and more girls participate in collision sports, such as basketball and soccer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACL injuries can result from direct trauma, landing off-balance, or \"cutting\" (ie, planting the foot while changing direction). The typical mechanism is twisting or hyperextension while the foot is planted and the knee extended [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/5\">",
"     5",
"    </a>",
"    ]. ACL injuries often are accompanied by other injuries, particularly involving the MCL and menisci [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/6\">",
"     6",
"    </a>",
"    ]. Most (75 percent) of ACL tears in young athletes are midsubstance; 20 percent occur at the femoral origin, and 5 percent at the tibial insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One-half to two-thirds of acute ACL injuries are accompanied by meniscal injury. However, only 40 percent of these meniscal injuries require surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Fifty percent of patients with acute ACL injuries have collateral ligament injuries, and 10 to 16 percent incur chondral injuries or patellar dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the typical scenario, the athlete with an ACL injury falls down and grabs the knee in pain immediately after the injury. He or she may report that the knee shifted. Approximately one-third of patients report that they heard or felt a pop inside the knee. The severity of pain does not necessarily correlate with the severity of the injury: complete ACL tears may be less painful than partial tears. As in other internal derangement injuries, the athlete has difficulty bearing weight or walking because of instability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=see_link&amp;anchor=H8#H8\">",
"     \"Anterior cruciate ligament injury\", section on 'Noncontact mechanism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=see_link&amp;anchor=H10#H10\">",
"     \"Anterior cruciate ligament injury\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute hemarthrosis often is present. The severity of hemarthrosis does not necessarily correlate with the severity of ACL injury. While hemarthrosis may develop within one hour of complete ACL tear, it may take up to 24 hours to develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=see_link&amp;anchor=H10#H10\">",
"     \"Anterior cruciate ligament injury\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anterior drawer test (",
"    <a class=\"graphic graphic_figure graphicRef53350 \" href=\"UTD.htm?41/61/42975\">",
"     figure 2",
"    </a>",
"    ), Lachman maneuver (",
"    <a class=\"graphic graphic_picture graphicRef65914 \" href=\"UTD.htm?16/54/17251\">",
"     picture 1",
"    </a>",
"    ), and pivot shift test (",
"    <a class=\"graphic graphic_figure graphicRef60176 \" href=\"UTD.htm?8/23/8563\">",
"     figure 3",
"    </a>",
"    ) are used to evaluate the integrity of the ACL. These maneuvers are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Posterior cruciate ligament",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior cruciate ligament (PCL) injuries can result from direct trauma to the upper anterior tibia when the knee is flexed (eg, a dashboard injury, a baseball runner sliding into the catcher, a fall off a bicycle), or by falling onto the flexed knee with the ankle in plantarflexion. The PCL also can be torn in a valgus or varus injury if the medial or lateral collateral ligament (the first lines of restraint for the PCL) is injured. Seventy percent of PCL injuries occur at the tibial insertion, 15 percent at the femoral origin, and 15 percent are midsubstance.",
"   </p>",
"   <p>",
"    In contrast to athletes who incur anterior cruciate ligament injuries, athletes with PCL injuries may perceive the injury to be minor, and return to play. The diagnosis of PCL tear is supported by a positive posterior drawer (",
"    <a class=\"graphic graphic_figure graphicRef74928 \" href=\"UTD.htm?39/29/40415\">",
"     figure 4",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    posterior sag test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    .) The treatment of these injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Lateral collateral ligament",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated lateral collateral ligament (LCL) tears are caused by an outwardly directed blow (varus force) to the medial aspect of the knee. Isolated LCL injuries are unusual in sports because the LCL usually is protected from direct varus force by the opposite leg. They are more common after high-velocity injuries (ie, motor vehicle accidents). Seventy-five percent of tears occur at the fibular head insertion, 20 percent at the femoral origin, and 5 percent are midsubstance. One-quarter are associated with superficial peroneal nerve injuries, 12 percent with chondral injuries, and 27 percent with meniscal injuries.",
"   </p>",
"   <p>",
"    LCL injuries are manifest by tenderness to palpation along the course of the LCL, and pain and laxity with varus testing (",
"    <a class=\"graphic graphic_picture graphicRef69222 \" href=\"UTD.htm?36/46/37600\">",
"     picture 2",
"    </a>",
"    ). As is the case with ACL injuries, the degree of pain does not reflect the severity of injury. Signs of grade 3 LCL injuries include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of the normally taut LCL when the patient sits with the involved leg in a figure-of-four position",
"     </li>",
"     <li>",
"      Increased laxity with varus testing at 30 degrees of flexion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gross instability on varus testing with the knee fully extended implies disruption of the capsular component of the LCL, the midportion of the PCL, and posterolateral corner instability, including the arcuate popliteal complex.",
"   </p>",
"   <p>",
"    The treatment of LCL injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Medial collateral ligament",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medial collateral ligament (MCL) tears are caused by an inwardly directed blow (valgus force) to the lateral aspect of the knee, as when a soccer player is taken down by a tackle, or when the inner edge of a ski becomes stuck in the snow, so that the foot is turned laterally while the remainder of the leg stays in a neutral position. About 65 percent of the tears occur at the femoral origin, 25 percent at the tibial insertion, and 10 percent are midsubstance. Lateral, rather than medial, meniscal injuries may accompany MCL injuries, which are caused by valgus force; the valgus force causes greater compression (the mechanism for meniscal injuries) of the lateral rather than the medial meniscus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3257?source=see_link&amp;anchor=H4#H4\">",
"     \"Medial collateral ligament injury of the knee\", section on 'Mechanism of injury and healing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The athlete may report a tearing sensation followed by medial knee pain, swelling, stiffness, and instability with lateral movements [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/5\">",
"     5",
"    </a>",
"    ]. MCL injuries are manifest by tenderness to palpation along the course of the MCL, particularly at the adductor tubercle, and pain and laxity with valgus testing (",
"    <a class=\"graphic graphic_picture graphicRef77592 \" href=\"UTD.htm?40/37/41552\">",
"     picture 3",
"    </a>",
"    ). Isolated MCL sprains are suggested with valgus stress at 30 degrees of flexion. On the other hand, gross laxity with valgus stress to the fully extended knee may indicate that the ACL is injured in addition to the MCL, since the ACL provides some medial stability when the leg is fully extended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the young athlete with acute knee pain or injury\", section on 'Medial collateral'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of MCL injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3257?source=see_link\">",
"     \"Medial collateral ligament injury of the knee\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Meniscal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of meniscal injuries increases with age. They reportedly occur in approximately 5 to 9 percent of children younger than 15 years, but rarely among children younger than 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/11\">",
"     11",
"    </a>",
"    ]. Meniscal injuries are caused when the athlete twists the leg while bearing weight (eg, when landing from a jump). Meniscal injuries are sometimes described as \"torn cartilage\" or a \"locked knee.\" The mechanisms for meniscal injuries are similar to those of ACL injuries, and these injuries often occur together, especially in athletes with open physes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. Weightbearing is usually limited by pain, and swelling typically develops within 24 hours.",
"   </p>",
"   <p>",
"    Mechanical symptoms may be more common than pain because only the periphery of the menisci contains nerve fibers. Mechanical symptoms include locking, popping, and catching. Other symptoms include swelling, pain with rotation or flexion (particularly at the extremes of those motions), pain along the joint line, weakness or giving way, and a generalized aching (particularly with chronic meniscal injury [see below]).",
"   </p>",
"   <p>",
"    Signs of meniscal injuries, which are similar to those in children with chondral fractures or injuries to the articular cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/5\">",
"     5",
"    </a>",
"    ], include joint line tenderness (",
"    <a class=\"graphic graphic_picture graphicRef70461 \" href=\"UTD.htm?12/54/13152\">",
"     picture 4",
"    </a>",
"    ), positive McMurray or modified McMurray test (",
"    <a class=\"graphic graphic_figure graphicRef57609 \" href=\"UTD.htm?6/33/6676\">",
"     figure 5",
"    </a>",
"    ), positive bounce-home test (",
"    <a class=\"graphic graphic_figure graphicRef55603 \" href=\"UTD.htm?35/24/36239\">",
"     figure 6",
"    </a>",
"    ), and restricted joint motion. These tests are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to the young athlete with acute knee pain or injury\", section on 'Range of motion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of meniscal injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patellar dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellar dislocation is usually a non-contact, weightbearing injury, although it can be caused by midair maneuvers involving forceful quadriceps contraction (eg, in diving or gymnastics). It typically occurs when the lower leg is externally rotated and the quadriceps muscle forcefully contracted to extend the knee. Patellar dislocation also can follow collision with another person, particularly if the knee sustains valgus (inward) force (football injuries). Patients with first-time dislocations often report hearing a loud sound and feeling a sensation of tearing and dislocation.",
"   </p>",
"   <p>",
"    Factors that predispose to patellar dislocation include weak vastus medialis obliquus (VMO) muscle (the principal dynamic medial stabilizer of the patella), inherent hyperelasticity, patella alta (high-riding patella), genu valgum (knock-knee) alignment (which favors lateral patellar tracking), and previous dislocations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24581?source=see_link&amp;anchor=H3#H3\">",
"     \"Patellar dislocations in children and adolescents\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patella almost always is dislocated laterally. In a patient with normal elasticity who dislocates the patella for the first time, lateral dislocation tears the medial patellar stabilizers, including the medial retinaculum, which causes a rapidly enlarging medial hematoma. In contrast, patients who have chronic subluxation of the patella, or in whom the patellofemoral joint is hypermobile, the bleeding and swelling after an episode may be minimal. Acute patellar dislocation can be complicated by bone and chondral fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24581?source=see_link&amp;anchor=H4#H4\">",
"     \"Patellar dislocations in children and adolescents\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute patellar dislocation may be difficult to distinguish from internal derangement, particularly if the mechanism of injury is unknown. Patients with patellar dislocation, and to a lesser extent, patellar subluxation, may have medial joint tenderness (",
"    <a class=\"graphic graphic_picture graphicRef70461 \" href=\"UTD.htm?12/54/13152\">",
"     picture 4",
"    </a>",
"    ) and pain with valgus testing (",
"    <a class=\"graphic graphic_picture graphicRef77592 \" href=\"UTD.htm?40/37/41552\">",
"     picture 3",
"    </a>",
"    ), symptoms that also are present in patients with MCL injury. The \"apprehension sign\" (apprehension when the examiner tries to push the patella laterally) (",
"    <a class=\"graphic graphic_figure graphicRef54035 \" href=\"UTD.htm?20/46/21216\">",
"     figure 7",
"    </a>",
"    ) can help distinguish these disorders. It is usually present in patients with patellar subluxation and absent in those with MCL injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the young athlete with acute knee pain or injury\", section on 'Patella'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to the young athlete with acute knee pain or injury\", section on 'Medial collateral'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Popliteus tendinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In popliteus tendinitis, the pain is localized to the posterior lateral knee. The pain is of relatively acute onset; it may occur during descent after the patient hikes up hills for a prolonged period, and is exacerbated by excessive forefoot pronation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This is because the popliteus muscle is a secondary restraint to anterior femoral translation in descent, and may be required to be more active as the quadriceps, hamstrings, and iliotibial band (ITB) muscles are exhausted with prolonged exercise. Chronic popliteus tendinitis may be confused with iliotibial band syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Muscle injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries to the muscles (eg, tears and strains) surrounding the knee may present acutely, or as an acute exacerbation of a chronic problem [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/14\">",
"     14",
"    </a>",
"    ]. The muscle groups most commonly injured include the hamstring, rectus femoris, gastrocnemius, and adductor longus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/15\">",
"     15",
"    </a>",
"    ]. The symptoms of muscle injury include local pain and limited flexibility. The muscles are tender to palpation, and a hematoma may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Referred hip pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute knee pain can be referred pain from primary pathology in the hip, such as arthritis, osteomyelitis, slipped capital femoral epiphysis (SCFE), and Legg-Calv&eacute;-Perthes disease.",
"   </p>",
"   <p>",
"    Adolescents with SCFE can present with knee or thigh pain. Examination of the knee is normal, but range of motion of the hips, particularly internal rotation, is often limited. Urgent referral is necessary since a delay in diagnosis can be catastrophic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link\">",
"     \"Slipped capital femoral epiphysis (SCFE)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Legg-Calv&eacute;-Perthes disease is the name for idiopathic avascular necrosis of the femoral head, which generally presents between 3 and 12 years of age with a peak incidence at five to seven years of age. Patients complain of acute or chronic knee pain with activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of hip pain in childhood\", section on 'Legg-Calv&eacute;-Perthes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of acute knee pain include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28455/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteosarcoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link&amp;anchor=H11#H11\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Clinical presentation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Osteomyelitis or septic arthritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical features of hematogenous osteomyelitis in children\", section on 'Children and adolescents'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link&amp;anchor=H6#H6\">",
"       \"Bacterial arthritis: Clinical features and diagnosis in infants and children\", section on 'Older children and adolescents'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute rheumatic fever (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"       \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"      </a>",
"      )In endemic regions, Lyme disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link&amp;anchor=H18#H18\">",
"       \"Lyme disease: Clinical manifestations in children\", section on 'Arthritis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pauciarticular juvenile arthritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link&amp;anchor=H2#H2\">",
"       \"Pauciarticular onset juvenile idiopathic arthritis\", section on 'Clinical presentation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hemarthrosis from hemophilia or other bleeding disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and diagnosis of hemophilia\", section on 'Hemarthrosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Leukemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\", section on 'Musculoskeletal pain'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8890394\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute injury related knee pain in the young athlete can be caused by internal derangement, musculotendinous strains, and contusions. Internal derangement is a nonspecific term that encompasses fractures, chondral lesions, and injuries to the ligaments or menisci. These injuries typically result in an inability to bear weight or pain on ambulation within a few minutes and knee swelling or acute hemarthrosis within 24 hours. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Fractures of the physes (growth plates) of the distal femur and proximal tibia are important causes of knee pain in the young athlete. Patients with these fractures typically have pain, swelling,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deformity at the site of injury and are unable to walk. (See",
"      <a class=\"local\" href=\"#H8889118\">",
"       'Fractures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ligamentous injuries are a common cause of acute knee pain in young athletes. They may occur in isolation or in association with other ligamentous, bone, or meniscal injuries. More significant injuries involve greater number of structures and have greater risk for neurovascular damage. Assessment of the mechanism of injury and clinical evaluation frequently identifies the affected ligament (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Ligament injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tibiofemoral dislocation, although rare, is the most serious of these injuries because it is associated with popliteal artery and peroneal nerve damage. Knee dislocation should be suspected in patients with significant knee instability after high-velocity trauma (eg, motor vehicle collision, skiing injury) or contact sport. Dislocations of the tibiofemoral joint of the knee are potentially limb-threatening injuries that require emergent reduction followed by careful neurovascular assessment (",
"      <a class=\"graphic graphic_algorithm graphicRef72754 \" href=\"UTD.htm?24/46/25327\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Knee dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute knee pain can be referred pain from primary pathology in the hip, such as arthritis, osteomyelitis, slipped capital femoral epiphysis (SCFE), and Legg-Calv&eacute;-Perthes disease. Adolescents with SCFE can present with knee or thigh pain. Examination of the knee is normal, but range of motion of the hips, particularly internal rotation, is often limited. Urgent referral is necessary since a delay in diagnosis can be catastrophic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link\">",
"       \"Slipped capital femoral epiphysis (SCFE)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Knee and lower leg. In: Essentials of Musculoskeletal Care, 2nd edition, Greene, WB (Eds), American Academy of Orthopedic Surgeons, Rosemont, IL 2001. p.341.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/2\">",
"      Iobst CA, Stanitski CL. Acute knee injuries. Clin Sports Med 2000; 19:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/3\">",
"      Arendt E, Dick R. Knee injury patterns among men and women in collegiate basketball and soccer. NCAA data and review of literature. Am J Sports Med 1995; 23:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/4\">",
"      Gray J, Taunton JE, McKenzie DC, et al. A survey of injuries to the anterior cruciate ligament of the knee in female basketball players. Int J Sports Med 1985; 6:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/5\">",
"      Anderson SJ. Lower extremity injuries in youth sports. Pediatr Clin North Am 2002; 49:627.",
"     </a>",
"    </li>",
"    <li>",
"     Anterior cruciate ligament tear. In: Essentials of Musculoskeletal Care, 2nd edition, Greene, WB (Eds), American Academy of Orthopedic Surgeons, Rosemont, IL 2001. p.360.",
"    </li>",
"    <li>",
"     Zachazewski, JE, Magee, DJ, Quillen, WS. Athletic Injuries and Rehabilitation, WB Saunders, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/8\">",
"      Bomberg BC, McGinty JB. Acute hemarthrosis of the knee: indications for diagnostic arthroscopy. Arthroscopy 1990; 6:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/9\">",
"      Lee K, Siegel MJ, Lau DM, et al. Anterior cruciate ligament tears: MR imaging-based diagnosis in a pediatric population. Radiology 1999; 213:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/10\">",
"      Graf BK, Lange RH, Fujisaki CK, et al. Anterior cruciate ligament tears in skeletally immature patients: meniscal pathology at presentation and after attempted conservative treatment. Arthroscopy 1992; 8:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/11\">",
"      DeHaven KE, Lintner DM. Athletic injuries: comparison by age, sport, and gender. Am J Sports Med 1986; 14:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/12\">",
"      Olson WR, Rechkemmer L. Popliteus tendinitis. J Am Podiatr Med Assoc 1993; 83:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/13\">",
"      Safran MR, Fu FH. Uncommon causes of knee pain in the athlete. Orthop Clin North Am 1995; 26:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/14\">",
"      Kibler WB. Clinical aspects of muscle injury. Med Sci Sports Exerc 1990; 22:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/15\">",
"      Garrett WE Jr. Muscle strain injuries. Am J Sports Med 1996; 24:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28455/abstract/16\">",
"      Barber FA, Prudich JF. Acute traumatic knee hemarthrosis. Arthroscopy 1993; 9:174.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6523 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-190.81.197.98-76CD966DD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28455=[""].join("\n");
var outline_f27_50_28455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8890394\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8889118\">",
"      Fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ligament injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Knee dislocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Anterior cruciate ligament",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Posterior cruciate ligament",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Lateral collateral ligament",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Medial collateral ligament",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Meniscal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patellar dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Popliteus tendinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Muscle injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Referred hip pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8890394\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6523\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6523|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/46/25327\" title=\"algorithm 1\">",
"      Management of knee dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6523|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/9/15510\" title=\"figure 1\">",
"      Neurovascular anatomy knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/61/42975\" title=\"figure 2\">",
"      Anterior drawer test2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/23/8563\" title=\"figure 3\">",
"      Pivot shift test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/29/40415\" title=\"figure 4\">",
"      Posterior drawer test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/33/6676\" title=\"figure 5\">",
"      McMurray test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/24/36239\" title=\"figure 6\">",
"      Bounce home test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/46/21216\" title=\"figure 7\">",
"      Patellar apprehension test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6523|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/54/17251\" title=\"picture 1\">",
"      Lachman test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/46/37600\" title=\"picture 2\">",
"      Varus stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/37/41552\" title=\"picture 3\">",
"      Valgus stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/54/13152\" title=\"picture 4\">",
"      Joint line palpation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6523|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/46/10987\" title=\"table 1\">",
"      Acute knee injury diagnosis - high school sports",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32138?source=related_link\">",
"      Anterior cruciate ligament injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=related_link\">",
"      Approach to the young athlete with acute knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8726?source=related_link\">",
"      Causes of chronic knee pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/5/7257?source=related_link\">",
"      Distal femoral fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38038?source=related_link\">",
"      Knee (tibiofemoral) dislocation and reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3257?source=related_link\">",
"      Medial collateral ligament injury of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=related_link\">",
"      Overview of hip pain in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24581?source=related_link\">",
"      Patellar dislocations in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42807?source=related_link\">",
"      Proximal tibial fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=related_link\">",
"      Treatment of knee injuries in the young athlete",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_50_28456="M mode echo mitral stenosis";
var content_f27_50_28456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73666%7ECARD%2F57949%7ECARD%2F65631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73666%7ECARD%2F57949%7ECARD%2F65631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis on M-mode echocardiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top tracing shows a normal anterior mitral leaflet (AL), showing early opening (E) due to passive left ventricle filling and the late leaflet opening due to atrial contraction (A). The bottom tracing is from a patient with mitral stenosis. In contrast to the normal valve, the stenotic valve is thicker, as indicated by the multiple lines rather than a single one; it never closes during diastole and the slope of closure (E to F slope) is reduced with a velocity of 20mm/sec; and the posterior leaflet (PL) moves in parallel to the anterior rather than independently. In this patient the A wave is lost because of atrial fibrillation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M-mode echocardiogram shows moderate mitral stenosis with concordant motion of the anterior and posterior mitral valve (MV) leaflets which are thickened and a reduced E-F slope, indicating a pressure gradient between the left atrium and ventricle during diastole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M-mode echocardiogram of severe mitral stenosis shows concordant motion of anterior and posterior mitral valve (MV) leaflets which are thickened. The E-F slope is flat, resulting from very elevated left atrial pressure throughout diastole, suggesting a marked gradient across the mitral valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28456=[""].join("\n");
var outline_f27_50_28456=null;
var title_f27_50_28457="Acupuncture";
var content_f27_50_28457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acupuncture",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28457/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28457/contributors\">",
"     Andrew C Ahn, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28457/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28457/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/50/28457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The word \"acupuncture\" is derived from the Latin words \"acus\" (needle) and \"punctura\" (penetration). Acupuncture originated in China approximately 2000 years ago and is one of the oldest medical procedures in the world.",
"   </p>",
"   <p>",
"    Over its long history and dissemination, acupuncture has diversified and encompasses a large array of styles and techniques. Common styles include Traditional Chinese, Japanese, Korean, Vietnamese, and French acupuncture, as well as specialized forms such as hand, auricular, and scalp acupuncture.",
"   </p>",
"   <p>",
"    Acupuncture also refers to a family of procedures used to stimulate anatomical points. Aside from needles, acupuncturists can incorporate manual pressure, electrical stimulation, magnets, low-power lasers, heat, and ultrasound.",
"   </p>",
"   <p>",
"    Despite this diversity, the techniques most frequently used and studied are manual manipulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrical stimulation of thin, solid, metallic needles inserted into skin. Except where specifically stated, \"acupuncture\" in this topic refers to these two most common procedures.",
"   </p>",
"   <p>",
"    A general discussion of acupuncture is presented here. Additional discussions of acupuncture for rheumatic conditions and for cancer are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7607?source=see_link\">",
"     \"Acupuncture for rheumatic conditions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link&amp;anchor=H27#H27\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Acupuncture and related therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise origin of acupuncture is a source of debate. There is no single archaeological finding that points to a momentary emergence of acupuncture. Rather evidence exists for a variety of potential antecedent practices like bloodletting, tattoos for religious purposes, and use of bones to extract abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     China",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first written document to record the use of acupuncture is the Nei Jing (Inner Classic of the Yellow Emperor) dated approximately 100 BC. It is a collection of 81 treatises divided into two parts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/2\">",
"     2",
"    </a>",
"    ]. By the time of its compilation, acupuncture was already a signature therapy of Chinese medicine.",
"   </p>",
"   <p>",
"    The importance of acupuncture as medical therapy emerged around the same time that Confucianism and Taoism gained prominence in China. These philosophies are imprinted in the fundamental principles of acupuncture theory, and their influence is patently evident throughout the ancient texts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Acupuncture underwent significant development and expansion within the ensuing 1500 years and arguably climaxed in the Ming era (1368-1644) when The Great Compendium of Acupuncture and Moxibustion was published in 1601 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/4\">",
"     4",
"    </a>",
"    ]. Afterwards, it experienced waxing and waning popularity due to political and social pressures arising from Western influences, but it gained a modern resurgence after Mao ZeDong encouraged its use among \"barefoot doctors\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically there are around 10,000 treatises on acupuncture from the centuries preceding the modern era [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/5\">",
"     5",
"    </a>",
"    ]. Past acupuncture scholars freely edited prior texts and added personal interpretations, commentaries, and clinical experiences [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, present copies of ancient texts often represent the work of multiple acupuncture scholars and demonstrate a medley of teachings, each susceptible to variable interpretations. This has contributed to the marked heterogeneity seen in acupuncture practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Asia and Europe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acupuncture was disseminated to Korea and Japan in the sixth century, to Southeast Asia around the ninth century through commercial trade routes from China, and to Europe as early as the sixteenth century when Asian texts and translations were brought back by traders and missionaries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/6\">",
"     6",
"    </a>",
"    ]. Acupuncture became relatively established in some parts of Europe, such as France, around the eighteenth century and persisted due to perpetual colonial influences (eg, Indochine) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States (US), traces of acupuncture appeared as early as 18th century and appeared in the early editions of William Osler's Principle and Practice of Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/7\">",
"     7",
"    </a>",
"    ]. However, acupuncture did not enter the mainstream until 1971, when a New York Times journalist, James Reston, visited China and reported his experiences with acupuncture for postoperative pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A survey from 2002 estimated that 8.2 million US adults had ever used acupuncture, and an estimated 2.1 million had used acupuncture in the previous year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/9\">",
"     9",
"    </a>",
"    ]. The five most commonly treated conditions were back pain, neck pain, joint pain, headache, and",
"    <span class=\"nowrap\">",
"     \"head/chest",
"    </span>",
"    cold\". Other commonly treated conditions include fatigue, anxiety, insomnia, and depression. Several surveys suggest that acupuncture is the complementary and alternative medicine (CAM) therapy most likely to be recommended by conventional medical professionals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acupuncture use is probably more prevalent in certain Asian immigrant populations such as Chinese and Vietnamese Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BASIC THEORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acupuncture's early development coincided with the rise and prominence of two major Chinese philosophies, Confucianism and Taoism. As a result, acupuncture theory is largely grounded in these philosophies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One notable, early influence of these philosophies was the recognition that one's observation and experience were sufficient to explain the human condition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/12\">",
"     12",
"    </a>",
"    ]. This was a significant departure from primordial Chinese healing arts which usually ascribed illness to some superstitious force or moral punishment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two philosophies, particularly Taoism, emphasized the importance of understanding the laws of nature and for humans to integrate and abide by these laws rather than to resist them. The human body was regarded as a microcosmic reflection of the macrocosm of the universe. For this reason, concepts used to explain nature, such as",
"    <span class=\"nowrap\">",
"     yin/yang",
"    </span>",
"    and Five Elements (described below), became central to acupuncture theory [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/3\">",
"     3",
"    </a>",
"    ]. The goal of the clinician was to maintain the body's harmonious balance both internally and in relation to the external environment.",
"   </p>",
"   <p>",
"    Eastern medicine values the clinician's initial assessment and encourages the practitioner to hone",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own intuition to extract additional subtleties. Eastern thought perceives the world as dynamic and interconnected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/13\">",
"     13",
"    </a>",
"    ]. To the acupuncturist, it makes little sense to isolate a symptom such as back pain. Symptoms necessarily arise from a particular context. Acupuncture treatments are therefore usually individualized, and two patients with the same symptoms often do not get the same treatment. The same patient also may not receive the same treatment on subsequent visits.",
"   </p>",
"   <p>",
"    Three important concepts in acupuncture are qi,",
"    <span class=\"nowrap\">",
"     yin/yang,",
"    </span>",
"    and Five Elements.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Qi (pronounced \"chee\") is frequently translated as \"vital energy\" [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/14\">",
"       14",
"      </a>",
"      ]. It is felt to permeate all things, may assume different forms, and travel through meridians located on the body. It can be described as stagnant, depleted, collapsed, or rebellious. Whether qi is a quantitative force or a metaphoric way of depicting and experiencing interconnections is not clear. It likely provides a rationale for explaining change and linking phenomena [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Yin and yang are felt to be complementary opposites and are used to describe all things in nature. Yin is used to represent more material, dense states of matter while yang represents more immaterial, rarefied states of matter [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/15\">",
"       15",
"      </a>",
"      ]. The interplay between the two opposites is dynamic and cyclical. To the acupuncturist, health is a constant state of dynamic balance and one must employ a series of qualitative assessments to establish a patient's present disposition (",
"      <a class=\"graphic graphic_table graphicRef59963 \" href=\"UTD.htm?5/60/6091\">",
"       table 1",
"      </a>",
"      ). The evaluation is more complex than merely designating a patient as \"more yin\" or \"more yang\". An intricate set of qualitative measures, examination tools, and symptom evaluations are used [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Five Elements along with",
"      <span class=\"nowrap\">",
"       yin/yang",
"      </span>",
"      theory form the basis of Chinese medical theory. The Five Elements are wood, water, fire, earth, and metal. These elements are not basic constituents of nature, but represent different basic processes, qualities, or phases of a cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/15\">",
"       15",
"      </a>",
"      ]. Each element can generate or counteract another element. Most vital organs, acupuncture meridians, emotions, and other health-related variable are assigned an element (",
"      <a class=\"graphic graphic_table graphicRef53247 \" href=\"UTD.htm?24/41/25243\">",
"       table 2",
"      </a>",
"      ), thus providing a global description of the balancing dynamics seen in each person.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Eastern Medical practitioner relies on these principles for diagnosis and treatment selection. Once the nature of imbalance is determined, the practitioner aims to shift the constitution towards balance with the use of various interventions. Acupuncture is one important option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACUPUNCTURE ENCOUNTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical acupuncture treatment begins with identification of the patient's constitutional pattern. To accomplish this, acupuncturists use the \"Four Pillars of Evaluation\": inspection, auscultation, inquiring, and palpation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to traditional Chinese medical theory, practically everything, such as skin, complexion, bones, channels, smells, sounds, mental state, preferences, emotions, demeanor, and body build reflects the state of the internal organs and can be used in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/15\">",
"     15",
"    </a>",
"    ]. The diagnostic evaluation may therefore be extensive, often incorporating seemingly unrelated symptoms (as an example, discerning one's incapacity to make decisions or dislike of speaking for complaints of abdominal pain) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/15\">",
"     15",
"    </a>",
"    ]. In Traditional Chinese Acupuncture, the tongue and radial pulse are often evaluated. In the Japanese style, strategic \"reflex points\" may be identified [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the diagnosis is established, fine metal needles are inserted into precisely defined points to correct disruption in harmony. Classic theory recognizes about 365 points, said to be located on 14 main channels (or meridians) connecting the body. The 14 main channels are associated with specific organs, although theoretically not in the anatomic sense to which biomedical clinicians are accustomed.",
"   </p>",
"   <p>",
"    Half are yin and other half are yang channels. Additional acupuncture points (both on and off channel) have been added with time and the total number of points has increased to at least 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/16\">",
"     16",
"    </a>",
"    ]. In practice, however, the repertoire of a typical acupuncturist may be only 150 points. Between 5 and 20 needles are used in a typical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/12\">",
"     12",
"    </a>",
"    ]. Each session usually lasts up to one hour, although sessions can be as short as 15 minutes. Once needles are inserted, they are often left for 10 to 15 minutes while the patient lies relaxed. Needles are removed at the end of the session. Treatments occur one to two times a week and the total number of sessions is variable, depending on the condition, disease severity, and chronicity.",
"   </p>",
"   <p>",
"    In Traditional Chinese Acupuncture, needle effectiveness is frequently measured by the elicitation of de qi [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/17\">",
"     17",
"    </a>",
"    ]. De qi is obtained by manipulation of the acupuncture needle and is perceived as an \"aching\" or \"throbbing\" sensation by the patient and a \"grasp\" by the acupuncturist [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/4,18-20\">",
"     4,18-20",
"    </a>",
"    ]. For the patient, a treatment session may be considered painful, although there is clear cultural and interpersonal variability. Other styles, such as Japanese acupuncture, tend to be more subtle and utilize more superficial needling with little or no manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/14,21\">",
"     14,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heat stimulation, a technique known as moxibustion, which burns the herb Artemisia Vulgaris near the acupuncture point, is sometimes used. Hand pressure is also sometimes applied. Numerous other techniques can also be used (eg, low-power laser, electricity, magnets, and ultrasound). The type of intervention and level of stimulation varies with acupuncture style and between acupuncturists. Some styles, such as auricular, hand, and scalp acupuncture, limit their stimulation to a particular body part.",
"   </p>",
"   <p>",
"    Acupuncture treatments are usually individualized, catered to the individual and not to the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/22\">",
"     22",
"    </a>",
"    ]. Two patients with identical problems will frequently get different treatments. Point combinations can also vary between sessions.",
"   </p>",
"   <p>",
"    Acupuncture is often used in conjunction with other modalities. Chinese herbal interventions have historically been the mainstay of East Asian therapy. Acupuncturists may also use massage, cupping (placing vacuum suction over point areas) and scarification [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lifestyle counseling, around issues such as diet, exercise, and mental health, is a component of acupuncture care. In addition, the acupuncture experience itself is purported to be therapeutic. Patients are frequently required to lay relaxed while the needles are left embedded in the skin. Consequently, the experience is frequently described as relaxing and soothing. Furthermore, acupuncturists historically have considered the patient-clinician relationship and therapeutic encounter itself to be inherently \"potent\" and sufficient to promote healing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROPOSED MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple physiologic models have been proposed to explain the effects of acupuncture. Various models have implicated cytokines, hormones (eg, cortisol and oxytocin), biomechanical effects, electromagnetic effects, the immune system, and the autonomic and somatic nervous systems.",
"   </p>",
"   <p>",
"    For many proposed models, the data have been either too inconsistent or inadequate to draw significant conclusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Endorphins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most thoroughly studied application of acupuncture is for pain relief. Studies performed in the 1970s and 1980s have contributed tremendously to our present understanding of acupuncture's analgesic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/23-41\">",
"     23-41",
"    </a>",
"    ]. According to this theory, acupuncture stimulation is associated with neurotransmitter effects such as endorphin release at both the spinal and supraspinal levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In support of this theory, there is evidence that opioid antagonists block the analgesic effects of acupuncture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast to this theory, however, the endorphin effects appear to be short-term, only lasting 10 to 20 minutes and possibly up to several days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/45\">",
"     45",
"    </a>",
"    ], while many acupuncture clinical trials have documented longer effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Additionally, endorphin release can be induced by strongly stimulating any free nerve ending or muscle afferents. The specificity of acupuncture point location and the rationale for needling certain points in various conditions remain unexplained.",
"   </p>",
"   <p>",
"    For these and other reasons, researchers have acknowledged the limitations of the endorphin-related mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Functional MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional MRI studies have demonstrated physiologic effects with acupuncture. In one study, needling Bladder Points located on the foot (purported to treat visual disorders) was associated with changes in MRI signals at the visual cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/49\">",
"     49",
"    </a>",
"    ]. Multiple other acupuncture-MRI studies have also shown effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Connective Tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another theory is that acupuncture points are associated with anatomic locations of loose connective tissue. A study that looked at points and meridians in the arm concluded that such an association was present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/54\">",
"     54",
"    </a>",
"    ]. It is possible that such an association might relate to the concept of \"grasp\" noted by practitioners [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Proposed indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been hundreds of controlled trials of acupuncture for various conditions. The best trials are discussed below (see",
"    <a class=\"local\" href=\"#H20\">",
"     'High-quality trials'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Conditions for which acupuncture has been studied and appears to have possible efficacy (whether or not it has greater efficacy than sham acupuncture) include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/57-61\">",
"       57-61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Postoperative nausea and vomiting [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chemotherapy induced nausea [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acute pain including dental pain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/65-67\">",
"       65-67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Headache [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/46,68,69\">",
"       46,68,69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chronic obstructive pulmonary disease (COPD) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/71\">",
"       71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Seasonal allergic rhinitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/72\">",
"       72",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acupuncture has been studied for many other conditions including stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], depression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/75\">",
"     75",
"    </a>",
"    ], fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/76\">",
"     76",
"    </a>",
"    ], and tobacco use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/77,78\">",
"     77,78",
"    </a>",
"    ], but the evidence is insufficient to recommend the use of acupuncture for these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acupuncture is generally safe, but can lead to the complications seen with any type of needle use. These include transmission of diseases, needle fragments left in the body, nerve damage, pneumothorax, pneumoperitoneum, organ puncture, cardiac tamponade, and osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Local complications include bleeding, contact dermatitis, infection, pain, and paresthesias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the variety of listed complications and the occasional case reports in major journals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/81-86\">",
"     81-86",
"    </a>",
"    ], major adverse events are exceedingly rare and are usually associated with poorly trained unlicensed acupuncturists [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study in Japan of 65,482 acupuncture treatments reported no major adverse events [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective investigation in Germany of 97,733 patients constituting 760,000 treatment sessions reported that the two most frequently reported adverse events were needling pain (3.3 percent) and hematoma (3.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/89\">",
"       89",
"      </a>",
"      ]. Potentially serious adverse events included two cases of pneumothorax. An asthma attack, a vasovagal reaction, an acute hypertensive crisis, and an exacerbation of depression were considered to be possibly related to treatment.",
"     </li>",
"     <li>",
"      Another two surveys performed in the United Kingdom totaling 66,000 treatments reported no serious adverse events [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/90,91\">",
"       90,91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, acupuncture is considered very safe if rates of adverse effects are compared to those seen in many pharmacologic treatments. Practitioners should use sterile needles to prevent transmission of disease. In the US, acupuncture practitioners are required to use disposable sterile needles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, local contraindications to acupuncture include active infection at insertion sites as well as malignancy at such sites, since there is a theoretical risk of causing metastatic dispersal of tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electroacupuncture should generally be avoided in patients with an automatic implantable cardioverter-defibrillator (AICD) or pacemaker [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/93\">",
"     93",
"    </a>",
"    ]. Any disruption of the skin should be avoided in patients with severe neutropenia as seen after myelosuppressive chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy is not an absolute contraindication, since acupuncture has been used and studied for gestational conditions such as breech presentation and pregnancy-associated nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/95-100\">",
"     95-100",
"    </a>",
"    ]. According to acupuncture theory, however, some points can induce labor, and the acupuncturist should be informed of the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bleeding disorders and use of anticoagulants are also not absolute contraindications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/103\">",
"     103",
"    </a>",
"    ]. Acupuncture needles are nearly always thinner than the intravenous catheters or phlebotomy needles routinely administered in hospitals. The acupuncturist should be notified of any bleeding risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is wide variability in skill level among acupuncture practitioners, including those licensed to perform the procedure. In the United States (US), identifying a good acupuncturist is typically by word of mouth.",
"   </p>",
"   <p>",
"    Referring clinicians and patients should attempt to identify acupuncturists who use sterile techniques and needles. In the US, acupuncturists should be certified by the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) or the American Board of Medical Acupuncture (ABMA); acupuncturists should be licensed if they are in one of the 40 states that have such licensure.",
"   </p>",
"   <p>",
"    Clinicians should try to identify acupuncturists who will work with medical treatments and who will not encourage patients to discontinue standard medical therapies. Referring clinicians should also consider insurance coverage.",
"   </p>",
"   <p>",
"    In the US, as long as the referring clinician appropriately diagnoses and manages a condition, referral of patients to an independent licensed practitioner for whom it's clear they have no supervisory role will not typically create a significant risk of legal liability [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US, approximately 70 percent of acupuncturists practice alone or in acupuncture groups; 30 percent work in multidisciplinary settings, usually in association with other CAM providers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     US insurance coverage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, Medicare and Medicaid do not cover acupuncture, but numerous other insurance carriers have some form of acupuncture coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/105\">",
"     105",
"    </a>",
"    ]. According to a 2004 Kaiser survey, the number of insurance carriers that cover acupuncture has increased steadily [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Employer coverage for acupuncture increased 14 percent (33 to 47 percent) from 2002 to 2004, making it one of the fastest-growing CAM therapies to be included as covered service for American workers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is variability in acupuncture coverage. The amount of coverage varies widely, ranging from a small discount to total coverage. Some plans require clinicians or chiropractors to perform services; some limit coverage to certain conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If cost is a major concern, patients should check their insurance carrier before using acupuncture. Given the number of sessions frequently required for treatment of a condition, the cost can accumulate and become substantial. This should be considered when referring a patient to an acupuncturist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL EVIDENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Difficulties in research",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the problems encountered with acupuncture randomized trials are shared by trials in many domains: inadequate sample size, lack of follow up, imprecise outcomes, improper statistical analysis, and others. Some problems, however, are particular to acupuncture research. Issues include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identifying an acupuncture treatment for a biomedically defined disease can be difficult. One disease in biomedicine can be many \"patterns\" within the Eastern medicine classification schema [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/12,108\">",
"       12,108",
"      </a>",
"      ]. As an example, diabetes can have Eastern medical diagnoses of \"stomach fire\", \"kidney fire\", or \"lung fire\" [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Individualized treatments seen in acupuncture run counter to the standardized treatments used in randomized trials. Researchers have tried to deal with this by performing pragmatic trials (where acupuncturists are given full freedom) or trials using semistandardized treatment (where acupuncturists are assigned mandatory points but given additional individualized options). Whether this latter approach approximates real acupuncture treatments is uncertain, as few studies have reported on the acupuncturists' perceptions of whether their treatments were constrained.",
"     </li>",
"     <li>",
"      Acupuncture entails many different styles and techniques. In the United States alone, at least eight different styles of acupuncture are taught in the various accredited schools [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/110\">",
"       110",
"      </a>",
"      ]. Differences exist on what points are to be needled, how the needle should be manipulated, how long the needle should be kept in, and what is the appropriate response elicited from the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/21\">",
"       21",
"      </a>",
"      ]. Thus it is difficult to know whether the results of a trial of single type of acupuncture can be generalized to other types.",
"     </li>",
"     <li>",
"      Due to the heterogeneity of acupuncture, an optimal control for one style may not be ideal for another.",
"     </li>",
"     <li>",
"      It is difficult to perform a double-blind acupuncture study. Acupuncturists are typically able to distinguish real treatment from sham treatment.",
"     </li>",
"     <li>",
"      Delivering acupuncture is not as simple as administering pills, and much like psychotherapy and surgery, experience may play a critical role in determining outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     High-quality trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the difficulties discussed above, a number of trials have compared active acupuncture with a sham control procedure that allows evaluation of the efficacy of acupuncture compared with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Low back pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-designed clinical trials have found that both acupuncture and sham acupuncture are more effective than control interventions for low back pain.",
"   </p>",
"   <p>",
"    In a systematic review of six randomized trials for chronic non-specific low back pain, acupuncture was found to have a small beneficial effect in reducing pain and improving functional status compared to sham, placebo, or other passive modalities at short-term (one month) and intermediate-term follow-up (three",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/111\">",
"     111",
"    </a>",
"    ]. Similarly, in five randomized trials, the combination of acupuncture plus an intervention was found to have a small beneficial effect in reducing pain and improving functional status compared to the intervention alone (physiotherapy, exercise, or standard medical care) at short-term and intermediate-term follow-up.",
"   </p>",
"   <p>",
"    A subsequent randomized trial in 638 adults with chronic low back pain compared acupuncture treatment individualized to the patient, acupuncture treatment standardized for low back pain, sham acupuncture, and usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/112\">",
"     112",
"    </a>",
"    ]. Patients received ten treatments over seven weeks. Patients were lying prone wearing a mask, and the sham therapy consisted of tapping and twisting a toothpick contained in an acupuncture needle guide tube against the skin for a few seconds at the points used in the standardized acupuncture intervention. At 10 and 20 minutes into the procedure a toothpick was touched to the skin and twisted at the same points. Patients apparently rated individualized, standardized, and sham acupuncture very similarly in terms of credibility. At eight weeks, back dysfunction scores improved by similar amounts in the individualized, standardized, and sham acupuncture groups and more than in the usual care group (4.4, 4.5, and 4.4 points versus 2.1 points, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Knee osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter randomized trial compared 10 sessions of acupuncture, sham acupuncture, or clinician visits in 1007 patients with chronic knee osteoarthritis who were also being treated with physical therapy and antiinflammatory medications as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/59\">",
"     59",
"    </a>",
"    ]. The primary outcome measure was the rate of success at 26 weeks, defined as a 36 percent improvement in a standardized osteoarthritis index.",
"   </p>",
"   <p>",
"    Acupuncture treatments were semistandardized: practitioners were instructed in certain points that were to be needled and could then choose individually to needle additional points. Sham acupuncture involved the use of points not deemed to be useful in the treatment of knee osteoarthritis administered at minimal needling depths.",
"   </p>",
"   <p>",
"    The researcher assessing endpoints was blinded to treatment assignment. Patient blinding between acupuncture and sham acupuncture was successful with about half of patients who thought they knew which treatment they were receiving guessing incorrectly.",
"   </p>",
"   <p>",
"    Rates of success were similar for acupuncture and sham acupuncture and greater than with conservative therapy (53 and 51 versus 29 percent).",
"   </p>",
"   <p>",
"    Two other high-quality randomized trials that compared acupuncture with sham acupuncture found some added benefit with acupuncture, however some blinding breakdown appears to have occurred in these trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/113,114\">",
"     113,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of randomized trials of acupuncture for knee osteoarthritis concluded that acupuncture may have had some additional measurable benefits compared with sham acupuncture but that the differences were too small to be clinically relevant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial published after the above meta-analysis compared six sessions of acupuncture, sham acupuncture (performed with a needle that retracted such that it did not penetrate the skin), and no additional therapy in 352 adults all of whom were treated with advice and exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/116\">",
"     116",
"    </a>",
"    ]. Patients found both acupuncture and sham acupuncture to be credible.",
"   </p>",
"   <p>",
"    The primary outcome was change in pain score at six months, and there were no significant differences between the three groups. At six weeks, patients treated with sham acupuncture had a small, but statistically significant improvement in pain compared with those receiving advice and exercise alone; true acupuncture showed no significant benefit compared with advice and exercise alone.",
"   </p>",
"   <p>",
"    Although like many other trials, this study found similar effects with acupuncture and sham acupuncture, the results were unusual in that the overall benefits of acupuncture and sham acupuncture were very small. This trial had fewer sessions of acupuncture or sham acupuncture than were used in most other studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared acupuncture, sham (minimal) acupuncture, and a waiting list control in 302 patients with migraine headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/69\">",
"     69",
"    </a>",
"    ]. Acupuncture and minimal acupuncture were administered in 12 sessions over eight weeks and the primary outcome measure was change in days of moderate-to-severe intensity headaches between the four weeks before and weeks 9 to 12 after randomization.",
"   </p>",
"   <p>",
"    Acupuncture treatments were semistandardized: practitioners were instructed in certain points that were to be needled and could then choose individually to needle additional points. Minimal acupuncture involved the use of points not deemed to be useful in the treatment of migraine administered at superficial needling depths.",
"   </p>",
"   <p>",
"    Patients were told that the study was intended to compare different types of acupuncture that had been associated with positive outcomes in clinical studies, and so were not made aware directly that there was a sham arm. Evaluation at the end of treatment found no significant differences in the expectations of benefit for patients assigned to the acupuncture and minimal acupuncture arms.",
"   </p>",
"   <p>",
"    Reduction in moderate-to-severe headache days were the same in the acupuncture and sham acupuncture groups, both of which were greater than in the waiting list control group (2.2 and 2.2 versus 0.8 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;These studies suggest that there is little difference in the effects on pain between acupuncture and sham acupuncture. A meta-analysis of randomized controlled trials of acupuncture for pain that included both sham acupuncture and no treatment arms (three-armed trials) found that the superiority of acupuncture over sham acupuncture, if real, appeared to be too small to be clinically important [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/117\">",
"     117",
"    </a>",
"    ]. A 2012 individual patient data meta-analysis concluded that acupuncture was somewhat more effective than sham therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/118\">",
"     118",
"    </a>",
"    ], but this meta-analysis included non-acupuncture sham therapies. Since the effects of sham acupuncture seem larger than most other placebo interventions, including other sham therapies in the analysis may have affected the results.",
"   </p>",
"   <p>",
"    One likely explanation for the results seen in high-quality randomized trials is that both acupuncture and sham acupuncture moderate pain through a strong placebo effect. An alternate possibility is that sham needling at nonacupuncture points to minimal depths has physiologic effects on pain. Against this latter possibility is the result of a randomized trial that examined the effects of acupuncture and sham acupuncture on postoperative nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/62\">",
"     62",
"    </a>",
"    ]. This trial used a sham device that did not penetrate the skin and still found similar effects with acupuncture and sham acupuncture.",
"   </p>",
"   <p>",
"    As discussed above, it is difficult to know whether acupuncture constrained by the requirements of a clinical trial has the same efficacy as when it is performed according to the practitioner's preferences. However the marked superiority of acupuncture and sham acupuncture over untreated controls demonstrates the strong effects of treatment seen even under study conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231910994\">",
"    <span class=\"h2\">",
"     Trials for conditions other than pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the trials that have used the best sham controls have involved treatment of pain conditions.",
"   </p>",
"   <p>",
"    A trial in patients with seasonal allergic rhinitis, all of whom had access to &ldquo;rescue medication&rdquo; treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    (and oral glucocorticoids if response was inadequate) compared acupuncture with sham acupuncture or no additional therapy beyond rescue medication [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/72\">",
"     72",
"    </a>",
"    ]. Symptom reduction was greater with acupuncture than with sham or rescue medication alone, but the improvements were small and may not have been clinically important. Although this trial included a sham arm, it appears that acupuncture and sham acupuncture were performed somewhat differently: patients treated with acupuncture had more needles placed on average (16 versus 10), and this may be a marker for other interactions between therapist and patient also being different during acupuncture and sham. Also, a larger fraction of patients in the acupuncture arm had high expectations for acupuncture efficacy at baseline (85 versus 73 percent). As such, this trial does not provide convincing evidence for a benefit of acupuncture beyond that of sham acupuncture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CREDENTIALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, the American Board of Medical Acupuncture (ABMA) certifies clinician acupuncturists while the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) certifies nonclinician acupuncturists.",
"   </p>",
"   <p>",
"    Certifications require passing a standardized exam and demonstration of adequate training. The typical education standard for an acupuncturist is between 2000 and 3000 hours of training in independently accredited master's degree three or four-year school [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28457/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some states in the US allow clinicians to practice acupuncture without additional education, most states require between 200 and 300 hours of special training.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/33/25105?source=see_link\">",
"       \"Patient information: Alternative medicine (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/51/21300?source=see_link\">",
"       \"Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The word \"acupuncture\" is derived from the Latin words \"acus\" (needle) and \"punctura\" (penetration) and can refer to a family of procedures used to stimulate anatomical points. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The traditional theory of acupuncture involves qi, yin and yang, and the Five Elements. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Basic theory'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a number of physiologic models that have been proposed to explain the effects of acupuncture. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Proposed mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acupuncture has been studied for many conditions including chronic and acute pain and postoperative and chemotherapy associated nausea. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Proposed indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there are difficulties in studying acupuncture randomized trials suggest that acupuncture and sham acupuncture may have similar efficacy. Given this, much or all of the effect of acupuncture may be related to the placebo effect. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'High-quality trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acupuncture is generally very safe as long as appropriate sterile techniques are followed. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Adverse events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with chronic pain, both acupuncture and sham acupuncture appear to have much greater efficacy than when patients are left untreated. We suggest that patients with chronic pain who are interested or open to acupuncture be referred for a trial of acupuncture when the availability of safe alternatives is limited (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients with other conditions may also benefit from a trial of acupuncture. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Clinical evidence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Unschuld P. Medicine in China: A History of Ideas, University of California Press, Berkeley 1985.",
"    </li>",
"    <li>",
"     Lu H. The Yellow Emperor's Book of Acupuncture, Academy of Oriental Heritage, Vancouver 1973.",
"    </li>",
"    <li>",
"     Kaptchuk T. The Web That Has No Weaver: Understanding Chinese Medicine, ed, McGraw-Hill, Lincolnwood, IL 2000.",
"    </li>",
"    <li>",
"     Helms J. Acupuncture Energetics: A Clinical Approach for clinicians, Medical Acupuncture Publishers, Berkeley 1995.",
"    </li>",
"    <li>",
"     Sivin N. Traditional Medicine in Contemporary China, The University of Michigan Press, Ann Arbor 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/6\">",
"      White A, Ernst E. A brief history of acupuncture. Rheumatology (Oxford) 2004; 43:662.",
"     </a>",
"    </li>",
"    <li>",
"     Osler, W. The Principles and Practices of Medicine. Appleton, New York 1892.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/8\">",
"      Reston, J. Now About My Operation in Peking. New York Times 1971; 1:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/9\">",
"      Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/10\">",
"      Astin JA, Marie A, Pelletier KR, et al. A review of the incorporation of complementary and alternative medicine by mainstream physicians. Arch Intern Med 1998; 158:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/11\">",
"      Ahn AC, Ngo-Metzger Q, Legedza AT, et al. Complementary and alternative medical therapy use among Chinese and Vietnamese Americans: prevalence, associated factors, and effects of patient-clinician communication. Am J Public Health 2006; 96:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/12\">",
"      Kaptchuk TJ. Acupuncture: theory, efficacy, and practice. Ann Intern Med 2002; 136:374.",
"     </a>",
"    </li>",
"    <li>",
"     Capra, F. The Tao of Physics, 4th ed, Shambhala, Boston 2000.",
"    </li>",
"    <li>",
"     Birch, S, Felt, R. Understanding Acupuncture. Churchill Livingstone, London 1999.",
"    </li>",
"    <li>",
"     Maciocia, G. The Foundations of Chinese Medicine. Churchill Livingstone, London 1989.",
"    </li>",
"    <li>",
"     Huai, L, Broffman, M, Pei, S. A Comprehensive Textbook. China Acupuncture and Moxibustion Supplies, Taiwan 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/17\">",
"      Abad-Alegr&iacute;a F, Pomar&oacute;n C. About the neurobiological foundations of the De-Qi--stimulus-response relation. Am J Chin Med 2004; 32:807.",
"     </a>",
"    </li>",
"    <li>",
"     Cheng, X. Chinese Acupuncture and Moxibustion. Foreign Language Press, Beijing, China 1987.",
"    </li>",
"    <li>",
"     Shanghai College of Traditional Medicine. Acupuncture. A Comprehensive Text. Eastland, Seattle, WA 1987.",
"    </li>",
"    <li>",
"     Beijing Shanghai aNCoTCM. Essentials of Chinese Acupuncture. Foreign Language Press, Beijing, China 1980.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/21\">",
"      Lee, BY, LaRiccia, PJ, Newberg, AB. Acupuncture in theory and practice part 2: Theoretical basis and physiologic effects. Hospital Physician 2004; :11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/22\">",
"      Paterson C, Britten N. Acupuncture as a complex intervention: a holistic model. J Altern Complement Med 2004; 10:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/23\">",
"      Pomeranz B, Cheng R, Law P. Acupuncture reduces electrophysiological and behavioral responses to noxious stimuli: pituitary is implicated. Exp Neurol 1977; 54:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/24\">",
"      Pomeranz B. Do endorphins mediate acupuncture analgesia? Adv Biochem Psychopharmacol 1978; 18:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/25\">",
"      Pomeranz B, Paley D. Electroacupuncture hypalgesia is mediated by afferent nerve impulses: an electrophysiological study in mice. Exp Neurol 1979; 66:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/26\">",
"      Pomeranz B, Bibic L. Electroacupuncture suppresses a nociceptive reflex: naltrexone prevents but does not reverse this effect. Brain Res 1988; 452:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/27\">",
"      Pomeranz B, Warma N. Electroacupuncture suppression of a nociceptive reflex is potentiated by two repeated electroacupuncture treatments: the first opioid effect potentiates a second non-opioid effect. Brain Res 1988; 452:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/28\">",
"      Pomeranz B. Scientific research into acupuncture for the relief of pain. J Altern Complement Med 1996; 2:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/29\">",
"      Pomeranz B, Cheng R. Suppression of noxious responses in single neurons of cat spinal cord by electroacupuncture and its reversal by the opiate antagonist naloxone. Exp Neurol 1979; 64:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/30\">",
"      Han JS. Acupuncture analgesia. Pain 1985; 21:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/31\">",
"      Han JS, Xie GX, Zhou ZF, et al. Acupuncture mechanisms in rabbits studied with microinjection of antibodies against beta-endorphin, enkephalin and substance P. Neuropharmacology 1984; 23:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/32\">",
"      Han JS, Tang J, Ren MF, et al. Central neurotransmitters and acupuncture analgesia. Am J Chin Med 1980; 8:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/33\">",
"      Han JS, Xie GX. Dynorphin: important mediator for electroacupuncture analgesia in the spinal cord of the rabbit. Pain 1984; 18:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/34\">",
"      Han JS, Xie GX, Zhou ZF, et al. Enkephalin and beta-endorphin as mediators of electro-acupuncture analgesia in rabbits: an antiserum microinjection study. Adv Biochem Psychopharmacol 1982; 33:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/35\">",
"      Han JS, Fei H, Zhou ZF. Met-enkephalin-Arg6-Phe7-like immunoreactive substances mediate electroacupuncture analgesia in the periaqueductal gray of the rabbit. Brain Res 1984; 322:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/36\">",
"      Han JS, Li SJ, Tang J. Tolerance to electroacupuncture and its cross tolerance to morphine. Neuropharmacology 1981; 20:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/37\">",
"      Cheng RS, Pomeranz B. Electroacupuncture analgesia could be mediated by at least two pain-relieving mechanisms; endorphin and non-endorphin systems. Life Sci 1979; 25:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/38\">",
"      Cheng RS, Pomeranz BH. Electroacupuncture analgesia is mediated by stereospecific opiate receptors and is reversed by antagonists of type I receptors. Life Sci 1980; 26:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/39\">",
"      Cheng R, McKibbin L, Roy B, Pomeranz B. Electroacupuncture elevates blood cortisol levels in naive horses; sham treatment has no effect. Int J Neurosci 1980; 10:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/40\">",
"      Cheng RS, Pomeranz B, Yu G. Electroacupuncture treatment of morphine-dependent mice reduces signs of withdrawal, without showing cross-tolerance. Eur J Pharmacol 1980; 68:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/41\">",
"      Cheng RS, Pomeranz B. Monoaminergic mechanism of electroacupuncture analgesia. Brain Res 1981; 215:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/42\">",
"      Han JS, Terenius L. Neurochemical basis of acupuncture analgesia. Annu Rev Pharmacol Toxicol 1982; 22:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/43\">",
"      Andersson S, Lundeberg T. Acupuncture--from empiricism to science: functional background to acupuncture effects in pain and disease. Med Hypotheses 1995; 45:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/44\">",
"      Ulett GA, Han S, Han JS. Electroacupuncture: mechanisms and clinical application. Biol Psychiatry 1998; 44:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/45\">",
"      Carlsson C. Acupuncture mechanisms for clinically relevant long-term effects--reconsideration and a hypothesis. Acupunct Med 2002; 20:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/46\">",
"      Vickers AJ, Rees RW, Zollman CE, et al. Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial. BMJ 2004; 328:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/47\">",
"      Guerra de Hoyos JA, Andr&eacute;s Mart&iacute;n Mdel C, Bassas y Baena de Leon E, et al. Randomised trial of long term effect of acupuncture for shoulder pain. Pain 2004; 112:289.",
"     </a>",
"    </li>",
"    <li>",
"     Change in the medical science of acupuncture. World Federation of Acupuncture and Moxibustion Societies, Kyoto 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/49\">",
"      Cho ZH, Chung SC, Jones JP, et al. New findings of the correlation between acupoints and corresponding brain cortices using functional MRI. Proc Natl Acad Sci U S A 1998; 95:2670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/50\">",
"      Fang JL, Krings T, Weidemann J, et al. Functional MRI in healthy subjects during acupuncture: different effects of needle rotation in real and false acupoints. Neuroradiology 2004; 46:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/51\">",
"      Wu MT, Sheen JM, Chuang KH, et al. Neuronal specificity of acupuncture response: a fMRI study with electroacupuncture. Neuroimage 2002; 16:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/52\">",
"      Yan B, Li K, Xu J, et al. Acupoint-specific fMRI patterns in human brain. Neurosci Lett 2005; 383:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/53\">",
"      Yoo SS, Teh EK, Blinder RA, Jolesz FA. Modulation of cerebellar activities by acupuncture stimulation: evidence from fMRI study. Neuroimage 2004; 22:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/54\">",
"      Langevin HM, Yandow JA. Relationship of acupuncture points and meridians to connective tissue planes. Anat Rec 2002; 269:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/55\">",
"      Langevin HM, Churchill DL, Wu J, et al. Evidence of connective tissue involvement in acupuncture. FASEB J 2002; 16:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/56\">",
"      Langevin HM, Churchill DL, Cipolla MJ. Mechanical signaling through connective tissue: a mechanism for the therapeutic effect of acupuncture. FASEB J 2001; 15:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/57\">",
"      Manheimer E, White A, Berman B, et al. Meta-analysis: acupuncture for low back pain. Ann Intern Med 2005; 142:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/58\">",
"      Furlan AD, van Tulder M, Cherkin D, et al. Acupuncture and dry-needling for low back pain: an updated systematic review within the framework of the cochrane collaboration. Spine (Phila Pa 1976) 2005; 30:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/59\">",
"      Scharf HP, Mansmann U, Streitberger K, et al. Acupuncture and knee osteoarthritis: a three-armed randomized trial. Ann Intern Med 2006; 145:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/60\">",
"      Brinkhaus B, Witt CM, Jena S, et al. Acupuncture in patients with chronic low back pain: a randomized controlled trial. Arch Intern Med 2006; 166:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/61\">",
"      White P, Lewith G, Prescott P, Conway J. Acupuncture versus placebo for the treatment of chronic mechanical neck pain: a randomized, controlled trial. Ann Intern Med 2004; 141:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/62\">",
"      Streitberger K, Diefenbacher M, Bauer A, et al. Acupuncture compared to placebo-acupuncture for postoperative nausea and vomiting prophylaxis: a randomised placebo-controlled patient and observer blind trial. Anaesthesia 2004; 59:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/63\">",
"      Ezzo J, Vickers A, Richardson MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol 2005; 23:7188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/64\">",
"      Ezzo JM, Richardson MA, Vickers A, et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev 2006; :CD002285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/65\">",
"      Smith CA, Collins CT, Cyna AM, Crowther CA. Complementary and alternative therapies for pain management in labour. Cochrane Database Syst Rev 2006; :CD003521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/66\">",
"      Rosted P. The use of acupuncture in dentistry: a review of the scientific validity of published papers. Oral Dis 1998; 4:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/67\">",
"      Ernst E, Pittler MH. The effectiveness of acupuncture in treating acute dental pain: a systematic review. Br Dent J 1998; 184:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/68\">",
"      Ahn AC, Kaptchuk TJ. Advancing acupuncture research. Altern Ther Health Med 2005; 11:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/69\">",
"      Linde K, Streng A, J&uuml;rgens S, et al. Acupuncture for patients with migraine: a randomized controlled trial. JAMA 2005; 293:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/70\">",
"      Flachskampf FA, Gallasch J, Gefeller O, et al. Randomized trial of acupuncture to lower blood pressure. Circulation 2007; 115:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/71\">",
"      Suzuki M, Muro S, Ando Y, et al. A randomized, placebo-controlled trial of acupuncture in patients with chronic obstructive pulmonary disease (COPD): the COPD-acupuncture trial (CAT). Arch Intern Med 2012; 172:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/72\">",
"      Brinkhaus B, Ortiz M, Witt CM, et al. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med 2013; 158:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/73\">",
"      Zhang SH, Liu M, Asplund K, Li L. Acupuncture for acute stroke. Cochrane Database Syst Rev 2005; :CD003317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/74\">",
"      Wu HM, Tang JL, Lin XP, et al. Acupuncture for stroke rehabilitation. Cochrane Database Syst Rev 2006; :CD004131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/75\">",
"      Smith CA, Hay PP, Macpherson H. Acupuncture for depression. Cochrane Database Syst Rev 2010; :CD004046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/76\">",
"      Mayhew E, Ernst E. Acupuncture for fibromyalgia--a systematic review of randomized clinical trials. Rheumatology (Oxford) 2007; 46:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/77\">",
"      White AR, Rampes H, Liu JP, et al. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev 2011; :CD000009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/78\">",
"      Tahiri M, Mottillo S, Joseph L, et al. Alternative smoking cessation aids: a meta-analysis of randomized controlled trials. Am J Med 2012; 125:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/79\">",
"      Lao L, Hamilton GR, Fu J, Berman BM. Is acupuncture safe? A systematic review of case reports. Altern Ther Health Med 2003; 9:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/80\">",
"      Ernst E, White AR. Prospective studies of the safety of acupuncture: a systematic review. Am J Med 2001; 110:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/81\">",
"      Vucicevic Z, Sharma M, Miklic S, Ferencic Z. Multiloculated pleural empyema following acupuncture. Infection 2005; 33:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/82\">",
"      Park JH, Shin HJ, Choo SJ, et al. Successful removal of migrated acupuncture needles in a patient with cardiac tamponade by means of intraoperative transesophageal echocardiographic assistance. J Thorac Cardiovasc Surg 2005; 130:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/83\">",
"      Saifeldeen K, Evans M. Acupuncture associated pneumothorax. Emerg Med J 2004; 21:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/84\">",
"      Studd RC, Stewart PJ. Images in clinical medicine. Intraabdominal abscess after acupuncture. N Engl J Med 2004; 350:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/85\">",
"      Cheng TO. Cardiac tamponade following acupuncture. Chest 2000; 118:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/86\">",
"      Woo PC, Li JH, Tang W, Yuen K. Acupuncture mycobacteriosis. N Engl J Med 2001; 345:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/87\">",
"      Vickers A, Wilson P, Kleijnen J. Acupuncture. Qual Saf Health Care 2002; 11:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/88\">",
"      Yamashita H, Tsukayama H, Tanno Y, Nishijo K. Adverse events in acupuncture and moxibustion treatment: a six-year survey at a national clinic in Japan. J Altern Complement Med 1999; 5:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/89\">",
"      Melchart D, Weidenhammer W, Streng A, et al. Prospective investigation of adverse effects of acupuncture in 97 733 patients. Arch Intern Med 2004; 164:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/90\">",
"      White A, Hayhoe S, Hart A, Ernst E. Adverse events following acupuncture: prospective survey of 32 000 consultations with doctors and physiotherapists. BMJ 2001; 323:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/91\">",
"      MacPherson H, Thomas K, Walters S, Fitter M. The York acupuncture safety study: prospective survey of 34 000 treatments by traditional acupuncturists. BMJ 2001; 323:486.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Guidelines on Basic Training and Safety in Acupuncture. Geneva,1999. p. 1-31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/93\">",
"      Lau EW, Birnie DH, Lemery R, et al. Acupuncture triggering inappropriate ICD shocks. Europace 2005; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/94\">",
"      Filshie J. Safety aspects of acupuncture in palliative care. Acupunct Med 2001; 19:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/95\">",
"      Stones RW, Vits K. Pelvic girdle pain in pregnancy. BMJ 2005; 331:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/96\">",
"      Cardini F, Lombardo P, Regalia AL, et al. A randomised controlled trial of moxibustion for breech presentation. BJOG 2005; 112:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/97\">",
"      Elden H, Ladfors L, Olsen MF, et al. Effects of acupuncture and stabilising exercises as adjunct to standard treatment in pregnant women with pelvic girdle pain: randomised single blind controlled trial. BMJ 2005; 330:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/98\">",
"      Lee H, Ernst E. Acupuncture for labor pain management: A systematic review. Am J Obstet Gynecol 2004; 191:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/99\">",
"      Neri I, Airola G, Contu G, et al. Acupuncture plus moxibustion to resolve breech presentation: a randomized controlled study. J Matern Fetal Neonatal Med 2004; 15:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/100\">",
"      Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev 2003; :CD000145.",
"     </a>",
"    </li>",
"    <li>",
"     Maciocia, G. Obstetrics &amp; Gynecology in Chinese Medicine. Churchill Livingstone, London 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/102\">",
"      Smith CA, Crowther CA. Acupuncture for induction of labour. Cochrane Database Syst Rev 2004; :CD002962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/103\">",
"      Sciammarella, J. Acupuncture in patients anticoagulated with warfarin. Medical Acupuncture 2002; 13:.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/104\">",
"      Studdert DM, Eisenberg DM, Miller FH, et al. Medical malpractice implications of alternative medicine. JAMA 1998; 280:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/105\">",
"      Lee, BY, LaRiccia, PJ, Newberg, AB. Acupuncture in Theory and Practice part 2: Clinical indications, efficacy, and safety. Hospital Physician 2004; :33.",
"     </a>",
"    </li>",
"    <li>",
"     The Kaiser Family Foundation, Health Research and Educational Trust. Employer Health Benefits 2004 Annual Survey. Kaiser Family Foundation, Menlo Park 2004.",
"    </li>",
"    <li>",
"     Devitt, M. Report: Insurance coverage for acupuncture on the rise. Acupuncture Today 2005; 6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/108\">",
"      Schnyer RN, Allen JJ. Bridging the gap in complementary and alternative medicine research: manualization as a means of promoting standardization and flexibility of treatment in clinical trials of acupuncture. J Altern Complement Med 2002; 8:623.",
"     </a>",
"    </li>",
"    <li>",
"     Kaptchuk, TJ. Web that has no weaver. 2nd ed. Contemporary (McGraw Hill), Chicago 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/110\">",
"      Seem, M. American acupuncture comes of age: Perspectives from the front line. Medical Acupuncture 1992; 4:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/111\">",
"      Rubinstein SM, van Middelkoop M, Kuijpers T, et al. A systematic review on the effectiveness of complementary and alternative medicine for chronic non-specific low-back pain. Eur Spine J 2010; 19:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/112\">",
"      Cherkin DC, Sherman KJ, Avins AL, et al. A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain. Arch Intern Med 2009; 169:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/113\">",
"      Berman BM, Lao L, Langenberg P, et al. Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med 2004; 141:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/114\">",
"      Witt C, Brinkhaus B, Jena S, et al. Acupuncture in patients with osteoarthritis of the knee: a randomised trial. Lancet 2005; 366:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/115\">",
"      Manheimer E, Linde K, Lao L, et al. Meta-analysis: acupuncture for osteoarthritis of the knee. Ann Intern Med 2007; 146:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/116\">",
"      Foster NE, Thomas E, Barlas P, et al. Acupuncture as an adjunct to exercise based physiotherapy for osteoarthritis of the knee: randomised controlled trial. BMJ 2007; 335:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/117\">",
"      Madsen MV, G&oslash;tzsche PC, Hr&oacute;bjartsson A. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups. BMJ 2009; 338:a3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28457/abstract/118\">",
"      Vickers AJ, Cronin AM, Maschino AC, et al. Acupuncture for chronic pain: individual patient data meta-analysis. Arch Intern Med 2012; 172:1444.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1390 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28457=[""].join("\n");
var outline_f27_50_28457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      China",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Asia and Europe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BASIC THEORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACUPUNCTURE ENCOUNTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROPOSED MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Endorphins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Functional MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Connective Tissue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL APPLICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Proposed indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Adverse events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      US insurance coverage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL EVIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Difficulties in research",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      High-quality trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Low back pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Knee osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Migraine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231910994\">",
"      Trials for conditions other than pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CREDENTIALING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/1390\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/1390|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/60/6091\" title=\"table 1\">",
"      Yin Yang symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/41/25243\" title=\"table 2\">",
"      Five elements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7607?source=related_link\">",
"      Acupuncture for rheumatic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/33/25105?source=related_link\">",
"      Patient information: Alternative medicine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/51/21300?source=related_link\">",
"      Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_50_28458="Porphyria cutanea tarda and hepatoerythropoietic porphyria";
var content_f27_50_28458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28458/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28458/contributors\">",
"     Ashwani K Singal, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28458/contributors\">",
"     Karl E Anderson, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28458/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28458/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/50/28458/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/50/28458/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/50/28458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4527356\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porphyria cutanea tarda (PCT) and hepatoerythropoietic porphyria (HEP) are porphyric conditions due to deficient activity of uroporphyrinogen decarboxylase (UROD), the fifth enzyme in the heme biosynthetic pathway (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .) Both are associated with chronic blistering photosensitivity, but are otherwise different clinically.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCT, the most common human porphyria, usually presents in mid or late life. Approximately 20 percent of patients with PCT are heterozygous for inherited UROD mutations, and are said to have familial (or type 2) disease, an autosomal dominant condition with low penetrance. Those without UROD mutations are said to have sporadic (type 1) PCT. In both type 1 and type 2 cases, the disease becomes manifest when hepatic UROD is inhibited, and its activity reduced to less than about 20 percent of normal, likely due to the presence of a uroporphomethene (ie, a partially oxidized uroporphyrinogen molecule) inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/2\">",
"       2",
"      </a>",
"      ]. Generation of this inhibitor requires a normal or increased amount of iron in the liver.",
"     </li>",
"     <li>",
"      HEP is the autosomal recessive form of familial PCT. This rare disease is associated with a more severe deficiency of UROD [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/3\">",
"       3",
"      </a>",
"      ], and usually presents in childhood with features that resemble congenital erythropoietic porphyria (CEP).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PCT and HEP will be reviewed here. The other porphyric conditions are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3066774\">",
"    <span class=\"h1\">",
"     PORPHYRIA CUTANEA TARDA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530116\">",
"    <span class=\"h2\">",
"     Definition and history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porphyria cutanea tarda (PCT) is due to an acquired deficiency of hepatic uroporphyrinogen decarboxylase (UROD) and is defined both by clinical features and biochemical findings. An inherited deficiency of UROD contributes in some cases. The chronic blistering skin manifestations are characteristic, but not specific. Highly carboxylated porphyrins (mostly uroporphyrin and heptacarboxyl porphyrins) accumulate in large amounts in the liver and then appear in plasma and urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1911, Gunther classified adults with painful skin lesions on sun-exposed areas of skin and increased porphyrin levels as chronic hematoporphyria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/5\">",
"     5",
"    </a>",
"    ]. This condition was renamed &ldquo;porphyria cutanea tarda&rdquo; by Waldenstrom in 1937 to emphasize the predominant cutaneous manifestations and relatively late onset of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/6\">",
"     6",
"    </a>",
"    ]. The disease was subsequently clearly differentiated from other porphyrias that cause blistering skin lesions.",
"   </p>",
"   <p>",
"    In the 1950s, exposure to hexachlorobenzene caused an outbreak of PCT in thousands of adults and children in eastern Turkey. This occurred after seed wheat, which had been treated with hexachlorobenzene as a fungicide, was consumed during a famine. Subsequently, it was shown that hexachlorobenzene and other chlorinated polyaromatic hydrocarbons can cause a deficiency of hepatic UROD activity in laboratory animals, with porphyrin elevations resembling those seen in PCT.",
"   </p>",
"   <p>",
"    The human disease has been associated with excess alcohol consumption, estrogen use, hepatic siderosis, hepatitis C, HIV, and smoking. The hepatic UROD inhibitor in PCT is an uroporphomethene, derived by oxidation of a bridge carbon in the uroporphyrinogen molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4530208\">",
"     'Decreased hepatic UROD activity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527372\">",
"    <span class=\"h2\">",
"     Prevalence and epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCT is reported worldwide. The prevalence of symptomatic disease has been estimated at approximately 1 in 25,000 in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/7\">",
"     7",
"    </a>",
"    ]. Onset is usually after age of 30, and is rare in children. Earlier onset is noted in some patients with UROD mutations or HFE mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527379\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCT is primarily characterized by manifestations due to skin and liver involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530124\">",
"    <span class=\"h3\">",
"     Skin findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous manifestations of PCT include blisters, bullae, increased fragility, scarring and hyper- and hypopigmentation affecting sun-exposed areas of the body, such as the backs of the hands, forearms, face, ears, neck, and feet (",
"    <a class=\"graphic graphic_picture graphicRef74528 \" href=\"UTD.htm?13/30/13794\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef78547 \" href=\"UTD.htm?13/47/14066\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56810 \" href=\"UTD.htm?10/4/10304\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/1,4,9,10\">",
"     1,4,9,10",
"    </a>",
"    ]. Bullae contain porphyrin-rich serous or serosanguinous fluid, and may be painful and become infected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/9\">",
"     9",
"    </a>",
"    ]. Hirsutism is also common, especially on the cheeks and forearms. Scarring may progress to &ldquo;pseudoscleroderma&rdquo; and with contraction and calcification resembling the cutaneous findings in systemic scleroderma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Porphyrins that accumulate in plasma and presumably also in the skin in PCT are photosensitizing. On exposure to light with a wavelength near 400 nm, porphyrins enter an excited state and release photons that activate oxygen in the tissues to the higher energy and more reactive singlet oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], which damages proteins, lipids, and basement membranes, with complement activation, mast cell degranulation, and release of transforming growth factor (TGF)-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Characteristic histological features include subepidermal blister formation and deposition of periodic-acid-Schiff (PAS) positive amorphous hyaline material containing immunoglobulin around the vessel walls, but with little inflammation unless there is secondary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527388\">",
"    <span class=\"h3\">",
"     Hepatic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCT is almost always associated with mild elevations in serum liver enzymes, especially serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Advanced liver disease is uncommon at initial presentation, but may be seen in older patients with recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/9,17\">",
"     9,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic injury in PCT can result from both porphyrin accumulation and some of the important susceptibility factors (eg, alcohol, hepatitis C virus). Massive porphyrin accumulation in the liver can be demonstrated by biochemical measurement or by reddish fluorescence on illumination of fresh liver tissue using a Wood's lamp (a UVA light source) or fluorescence microscopy. Accumulated porphyrins are mostly uroporphyrin and heptacarboxyl porphyrin, and characteristic birefringent needle-shaped inclusions are evident histologically [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/18\">",
"     18",
"    </a>",
"    ]. Nonspecific histopathologic findings may include varying degrees of siderosis, steatosis, portal triaditis, focal lobular necrosis, and periportal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/9,19,20\">",
"     9,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with PCT have an increased long-term risk for cirrhosis and hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/9,19,21,22\">",
"     9,19,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527395\">",
"    <span class=\"h2\">",
"     Susceptibility factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human PCT is a highly heterogeneous disease, in that multiple factors in various combinations contribute to susceptibility in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/23\">",
"     23",
"    </a>",
"    ]. Most of these factors contribute to iron accumulation or oxidative stress in hepatocytes. In one series, three or more simultaneous susceptibility factors were identified in 70 percent of 143 patients with documented PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/23\">",
"     23",
"    </a>",
"    ]. Although many of these factors are highly prevalent in PCT, none is found in all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530131\">",
"    <span class=\"h3\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of patients with PCT have inherited a mutation in the uroporphyrinogen decarboxylase (UROD) enzyme from one parent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Multiple mutations have been described in different families with PCT and hepatoerythropoietic porphyria (HEP), including missense and nonsense mutations, deletions and insertions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/24-29\">",
"     24-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heterozygosity for a UROD mutation results in half-normal UROD activity in all tissues from birth. However, this reduction is not sufficient to cause PCT. Patients with UROD mutations who develop PCT have one or more other inciting factors that further reduce hepatic UROD activity. Reduction of UROD activity to less than 20 percent of normal is required to cause overt, symptomatic PCT. If clinical manifestations develop, these patients with UROD mutations are classified as having familial (type 2) PCT.",
"   </p>",
"   <p>",
"    Most patients heterozygous for a UROD mutation will not develop symptomatic PCT. However, it is reported that greater than 30 percent of these asymptomatic carriers of UROD mutations will have increased urinary porphyrins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other genetic susceptibility factors for PCT include mutations in the HFE gene and CYP1A2 variants, which cause increased iron absorption and increased CYP1A2 activity, respectively. (See",
"    <a class=\"local\" href=\"#H4530138\">",
"     'Iron'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4530208\">",
"     'Decreased hepatic UROD activity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530138\">",
"    <span class=\"h3\">",
"     Iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCT is an iron-dependent disease; its clinical expression is highly correlated with the presence of iron in the liver. However, the dose-response relationship between hepatic iron levels and the development of PCT varies among patients, because PCT can develop in the presence of both normal and increased hepatic iron stores.",
"   </p>",
"   <p>",
"    Support for the association between hepatic iron and PCT comes from several observations: hepatic siderosis is found in the great majority of patients with PCT who undergo liver biopsy; iron deficiency protects against the development of PCT in humans and animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/1,31,32\">",
"     1,31,32",
"    </a>",
"    ]; and repeated phlebotomy to reduce hepatic iron content is effective and the most widely accepted treatment. Moreover, a number of known susceptibility factors may increase iron absorption or retention. (See",
"    <a class=\"local\" href=\"#H4527453\">",
"     'Repeated phlebotomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Marked iron overload is sometimes seen, but is unusual. Serum ferritin levels are usually either normal or modestly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/33-39\">",
"     33-39",
"    </a>",
"    ]. In one study, for example, high hepatic iron levels, as measured by MRI, were found in only 11 of 20 patients with PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/39\">",
"     39",
"    </a>",
"    ]. A high prevalence of PCT in Sub-Saharan Africa has been attributed to high dietary iron intake with a presumed genetic component [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H10#H10\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'African iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is an increased prevalence of HFE mutations in PCT, although clinically overt hemochromatosis is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/17,40,41\">",
"     17,40,41",
"    </a>",
"    ]. As an example, in one study, C282Y homozygosity was detected in 19 percent of 108 patients with PCT; 7 percent were compound heterozygotes",
"    <span class=\"nowrap\">",
"     (C282Y/H63D)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/40\">",
"     40",
"    </a>",
"    ]. In a large meta-analysis of disease associations with HFE genotypes, PCT was most strongly associated with the",
"    <span class=\"nowrap\">",
"     C282Y/C282Y",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     C282Y/H63D",
"    </span>",
"    genotypes (odds ratios 48 and 8.1, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/42\">",
"     42",
"    </a>",
"    ]. These HFE mutations result in impaired secretion of hepcidin by the liver, resulting in unregulated intestinal iron absorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"     \"Regulation of iron balance\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dysregulation of hepcidin production by the liver has been demonstrated in PCT patients even in the absence of HFE mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/43\">",
"     43",
"    </a>",
"    ], which helps explain increased absorption of iron in this disease, along with the development of iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530145\">",
"    <span class=\"h3\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCT was initially described as a disease of males with alcohol abuse, and alcohol has been reported as an important and common susceptibility factor in many series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/9,17,23,44\">",
"     9,17,23,44",
"    </a>",
"    ]. For example, in one large series, 87 percent of PCT patients reported excess alcohol intake [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the disease is not common among alcoholics. In one report of 360 patients with alcoholic cirrhosis followed for 10 years, only 2 percent had PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/45\">",
"     45",
"    </a>",
"    ]. Alcohol may contribute by down-regulation of hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], increasing oxidative stress, and by induction of cytochrome P450 enzymes (CYPs), perhaps including CYP2E1 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530152\">",
"    <span class=\"h3\">",
"     Smoking and cytochrome P450 enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed below, CYP1A2 may be involved in generation of the hepatic UROD inhibitor in PCT, and exposure to polycyclic aromatic hydrocarbons in cigarette smoke may contribute by inducing this enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/2\">",
"     2",
"    </a>",
"    ]. In a large series, 81 percent of patients with PCT were smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/23\">",
"     23",
"    </a>",
"    ]. In a group of PCT patients without UROD mutations, disease onset was earlier among smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A genetic polymorphism that favors greater inducibility of CYP1A2 has been found to be more common in PCT patients than in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530159\">",
"    <span class=\"h3\">",
"     Hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A strong association between hepatitis C virus infection and PCT was first reported in 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/52\">",
"     52",
"    </a>",
"    ]. Prevalences have ranged from 8 to 85 percent in reports from various countries, and are higher in the United States and southern Europe than in northern Europe and eastern Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/9,17,40,41,44\">",
"     9,17,40,41,44",
"    </a>",
"    ]. For example, prevalence of this viral infection is low in Norway, where none of 50 consecutive PCT patients tested positive for this infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/53\">",
"     53",
"    </a>",
"    ]. These variations presumably reflect differences in hepatitis C prevalence in at risk populations in various countries. Hepatitis C may be more common in PCT patients with advanced fibrosis or cirrhosis than in patients with less advanced hepatic damage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Anti-HCV antibodies in the absence of circulating HCV RNA are rare in PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/23,55,56\">",
"     23,55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This viral infection may contribute to the development of PCT by increasing oxidative stress in hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/57\">",
"     57",
"    </a>",
"    ], and increasing iron absorption by dysregulation of hepcidin production by the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/58\">",
"     58",
"    </a>",
"    ]. Other potential mechanisms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30421?source=see_link&amp;anchor=H6#H6\">",
"     \"Porphyria cutanea tarda and hepatitis C virus infection\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530166\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCT was first reported in patients with HIV infection in 1987, and many additional cases have been described since then [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. PCT may occur early or late in the course of HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. A mechanism whereby HIV infection might contribute to development of this porphyria has not been established. Co-infection with hepatitis C was found in only half of the cases in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530173\">",
"    <span class=\"h3\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of estrogens in oral contraceptives or for estrogen replacement after menopause is commonly identified in women as a susceptibility factor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/9,17,44,63-65\">",
"     9,17,44,63-65",
"    </a>",
"    ]. Estrogen was a factor in 66 percent of women with PCT in a one series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/23\">",
"     23",
"    </a>",
"    ]. In the past, this association was also described in men, when estrogens were commonly used for treatment of advanced prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/66\">",
"     66",
"    </a>",
"    ]. PCT has been reported uncommonly during pregnancy; this association may be due to chance. The mechanism of precipitation of PCT by estrogens is unclear. Estrogens undergo redox cycling and cause oxidative damage in the kidney of rodents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/67\">",
"     67",
"    </a>",
"    ], but this has not been demonstrated in the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530180\">",
"    <span class=\"h3\">",
"     Chemical exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large outbreak of PCT resulting from ingestion of hexachlorobenzene was described in Turkey in the 1950s (referred to in the past as &ldquo;toxic porphyria&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Smaller outbreaks have been associated with industrial exposure to tetrachlorodibenzo-p-dioxin (TCDD) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/70\">",
"     70",
"    </a>",
"    ]. Sporadic cases attributed to exposure to other chemicals such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    and diazinon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/71,72\">",
"     71,72",
"    </a>",
"    ] are of uncertain significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530187\">",
"    <span class=\"h3\">",
"     Other associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCT has also been associated with systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/73\">",
"     73",
"    </a>",
"    ], but other coexisting factors were not evaluated. Diabetes mellitus and hepatic steatosis, which can cause oxidative damage in the liver, have been prevalent in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/9,74\">",
"     9,74",
"    </a>",
"    ]. The disease is sometimes seen in patients with myeloproliferative neoplasms and other bone marrow disorders, usually in association with substantial iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530201\">",
"    <span class=\"h3\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCT may occur in patients on hemodialysis or peritoneal dialysis for advanced chronic renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/76,77\">",
"     76,77",
"    </a>",
"    ], often with associated iron overload. The disease is often especially severe in such cases, reflecting plasma porphyrin levels that may be much higher than in patients with normal renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527402\">",
"    <span class=\"h2\">",
"     Etiology and pathogenesis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530208\">",
"    <span class=\"h3\">",
"     Decreased hepatic UROD activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uroporphyrinogen decarboxylase (UROD) is the fifth enzyme in the heme biosynthetic pathway (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef54358 \" href=\"UTD.htm?0/9/155\">",
"     table 1",
"    </a>",
"    ). It is found in the cytosol, and it catalyzes the four-step decarboxylation of uroporphyrinogen to coproporphyrinogen, which have 8 and 4 carboxyl groups, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. The four carboxyl groups are removed sequentially in a clockwise fashion starting from ring D. The enzyme has greater affinity for uroporphyrinogen III than uroporphyrinogen I.",
"   </p>",
"   <p>",
"    PCT results from a decrease in the activity of hepatic UROD, to approximately 20 percent of normal. A UROD inhibitor has been identified from liver extracts, in murine models of PCT, as an uroporphomethene, which is derived by oxidation of one of the four bridge carbons in the uroporphyrinogen macromolecule [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/2\">",
"     2",
"    </a>",
"    ]. This inhibitor appears to be stable within the enzyme active site but is unstable when free in solution. Its formation from uroporphyrinogen I or III may be catalyzed by CYP1A2 in the presence of iron [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/2\">",
"     2",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef67596 \" href=\"UTD.htm?22/31/23037\">",
"     figure 2",
"    </a>",
"    ). Iron does not directly inhibit UROD, and it is not understood how iron contributes to generation of the uroporphomethene inhibitor of UROD.",
"   </p>",
"   <p>",
"    A heterozygous UROD mutation (found in approximately 20 percent of PCT patients) can reduce UROD activity in liver and all other tissues to 50 percent of normal, but other factors and generation of the UROD inhibitor are necessary for hepatic UROD activity to decrease further in these individuals and cause PCT to develop. (See",
"    <a class=\"local\" href=\"#H4530131\">",
"     'Genetic susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The rate-limiting enzyme for heme synthesis in liver is the house-keeping form of delta-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    synthase (ALAS1). Only a 15 to 20 percent increase in ALAS1 activity is required to account for the degree of excess porphyrin production in PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/1\">",
"     1",
"    </a>",
"    ]. Therefore, marked upregulation of ALAS1 is not thought to occur in PCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link&amp;anchor=H4#H4\">",
"     \"Porphyrias: An overview\", section on 'Regulation of heme synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527411\">",
"    <span class=\"h3\">",
"     Porphyrin accumulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Markedly decreased activity of hepatic UROD leads to accumulation of large amounts of uroporphyrinogen and hepta-, hexa-, and penta-carboxyl porphyrinogen in the liver, mostly as the corresponding oxidized porphyrins. Substantial amounts of these porphyrins accumulate in the liver, and then appear in plasma and urine. The resulting pattern of excess porphyrins, consisting of both I and III isomers, is complex, but characteristic (",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 2",
"    </a>",
"    ). These highly carboxylated porphyrins are water soluble, and therefore mostly excreted in urine, but some also appear in feces.",
"   </p>",
"   <p>",
"    Other porphyrin metabolic changes result from UROD deficiency, in that pentacarboxyl porphyrinogen accumulates and is further metabolized by coproporphyrinogen oxidase, the sixth enzyme in the pathway, to dehydro-isocoproporphyrinogen, an atypical tetracarboxyl porphyrinogen. After oxidation, this appears in feces and urine as isocoproporphyrins, with additional modifications by intestinal bacteria (",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527425\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Highly carboxylated porphyrins (uroporphyrin and heptacarboxyl porphyrin usually exceed hexa- and penta-carboxyl porphyrins) are increased in patients with PCT, especially in liver, plasma, and urine (",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 2",
"    </a>",
"    ). Total fecal porphyrins may be normal or moderately increased with a complex pattern including the presence of isocoproporphyrins; heptacarboxyl porphyrins may exceed hexacarboxyl and pentacarboxyl porphyrins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/1\">",
"     1",
"    </a>",
"    ]. Urinary delta-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    may be modestly increased, but porphobilinogen excretion is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527432\">",
"    <span class=\"h2\">",
"     Liver findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum transaminases are elevated in almost all cases. Liver tissue on biopsy shows marked reddish fluorescence when viewed under long wave UV light, reflecting large amounts of porphyrins. The red fluorescence does not intensify on oxidation, suggesting that the accumulated porphyrins are in their oxidized form and are not porphyrinogens. Microscopy shows these as needle shaped crystals within hepatocytes. (See",
"    <a class=\"local\" href=\"#H4527388\">",
"     'Hepatic findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527439\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blistering skin lesions on the backs of the hands and other sun exposed areas of skin should suggest the diagnosis of PCT. It is essential to confirm the diagnosis of PCT biochemically, because identical skin lesions can be seen in a number of other porphyrias, especially variegate porphyria (VP) and less commonly hereditary coproporphyria (HCP) (",
"    <a class=\"graphic graphic_table graphicRef80601 \" href=\"UTD.htm?31/63/32765\">",
"     table 3",
"    </a>",
"    ), and in pseudoporphyria.",
"   </p>",
"   <p>",
"    PCT is supported by demonstrating a marked increase in porphyrins in plasma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine, with a predominance of uroporphyrin and heptacarboxyl porphyrins, and usually lesser amounts of hexa- and penta-carboxyl porphyrins. Erythrocyte porphyrins are normal or only modestly increased. A total plasma porphyrin measurement may be most useful for initial screening. Fluorescence scanning of diluted plasma at a pH of 7.4 to determine the peak wavelength is useful for rapidly distinguishing PCT from VP (",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Elevation in isocoproporphyrins, which is more readily demonstrated in feces than urine, also helps confirm the diagnosis, but is usually not essential [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/81\">",
"     81",
"    </a>",
"    ]. Erythrocyte porphyrins are normal or modestly increased in PCT, in contrast to marked elevations in congenital erythropoietic porphyria (CEP), hepatoerythropoietic porphyria (HEP), and erythropoietic protoporphyria (EPP).",
"   </p>",
"   <p>",
"    Measurement of erythrocyte UROD activity is useful in patients with a confirmed diagnosis of PCT to identify those with UROD mutations, who are then classified as familial (type 2) disease. However, molecular studies are most accurate in detecting these mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After the diagnosis of PCT is confirmed, patients should be evaluated for the presence of susceptibility factors discussed above, as this can affect management [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/23,83,84\">",
"     23,83,84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4527395\">",
"     'Susceptibility factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H962869007\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different porphyric conditions and some medical conditions may be associated with cutaneous lesions similar to those seen in PCT. Blistering and scarring are usually more severe in CEP and HEP than in PCT. EPP is distinguishable from PCT by nonblistering and immediate photosensitivity, usual onset early in life, and by laboratory testing. The table indicates the major biochemical findings associated with the cutaneous porphyrias (",
"    <a class=\"graphic graphic_table graphicRef80601 \" href=\"UTD.htm?31/63/32765\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other differential diagnostic points include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevations in urine porphyrins occur in many medical conditions, especially liver and bone marrow diseases. In contrast to PCT, coproporphyrin usually predominates when urine porphyrins are nonspecifically elevated in conditions other than porphyria.",
"     </li>",
"     <li>",
"      Measurement of fecal porphyrins is needed to document hereditary coproporphyria (HCP) as a cause of coproporphyrinuria.",
"     </li>",
"     <li>",
"      Variegate porphyria (VP) is diagnosed by characteristic elevations in plasma and fecal porphyrins.",
"     </li>",
"     <li>",
"      Total plasma porphyrins can be elevated in cholestasis and renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/81,85\">",
"       81,85",
"      </a>",
"      ], but usually less than in PCT and other porphyrias causing blistering skin lesions. Plasma porphyrin measurements are essential for evaluating patients with advanced renal disease and skin lesions suggesting PCT [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rare cases of primary hepatic tumors with cutaneous lesions suggesting PCT have been described, suggesting that porphyrins may be overproduced by the tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]. However, these cases are not well documented biochemically or at the molecular level.",
"     </li>",
"     <li>",
"      Pseudoporphyria is a condition with skin lesions resembling PCT but without significant porphyrin elevations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/88\">",
"       88",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21111?source=see_link\">",
"       \"Pseudoporphyria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527446\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCT is the most readily treated type of porphyria. The preferred treatment at most centers is repeated phlebotomy, whether or not there is evidence of iron overload. A low-dose regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    is a suitable alternative if phlebotomies cannot be tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/4,83\">",
"     4,83",
"    </a>",
"    ]. Remission can be achieved within approximately six months in most cases. Until then, patients should",
"    <strong>",
"     avoid",
"    </strong>",
"    exposure to sunlight by wearing protective clothing. The skin lesions may be painful and require oral analgesics. Affected areas should be kept clean and skin infections treated with antibiotics. Topical steroids are of little or no benefit.",
"   </p>",
"   <p>",
"    Patients are advised to cease use of alcohol and to stop smoking. Estrogens should be discontinued at least until remission is achieved, after which an estrogen patch may be used safely, if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/89\">",
"     89",
"    </a>",
"    ]. Drugs known to exacerbate acute porphyrias are seldom reported to precipitate PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/90\">",
"     90",
"    </a>",
"    ]. However, they may contribute and should be avoided when possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link&amp;anchor=H7#H7\">",
"     \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Drugs and chemicals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527453\">",
"    <span class=\"h3\">",
"     Repeated phlebotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of phlebotomy has been recognized and widely reported for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/91-99\">",
"     91-99",
"    </a>",
"    ]. The rationale includes evidence that PCT depends on the presence of hepatic iron, including animal studies showing that iron depletion protects against development of uroporphyria and UROD inhibition (",
"    <a class=\"graphic graphic_figure graphicRef67596 \" href=\"UTD.htm?22/31/23037\">",
"     figure 2",
"    </a>",
"    ). The recommended approach is to remove one unit of whole blood (450 mL) at intervals of approximately two weeks until the serum ferritin is reduced to below approximately 20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    which is near the lower limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/92,98,100\">",
"     92,98,100",
"    </a>",
"    ]. The hemoglobin or hematocrit is followed to prevent significant anemia.",
"   </p>",
"   <p>",
"    Severe iron overload is uncommon in PCT, such that most patients require only six to eight phlebotomies in order to reach the target ferritin level. At that point, phlebotomy should be stopped, even if skin lesions are still present and porphyrins are not yet normal. The large amounts of porphyrins in the liver are mobilized and excreted gradually, and porphyrin levels will continue to decrease. Additional phlebotomies are of no benefit and may cause symptomatic iron deficiency anemia. It is most convenient to monitor improvement by measuring total plasma porphyrins rather than urine porphyrins.",
"   </p>",
"   <p>",
"    Phlebotomy achieves remission in nearly all patients with PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/91-96,101-103\">",
"     91-96,101-103",
"    </a>",
"    ]. Lack of response suggests that the target ferritin has not yet been reached, or that the patient has a type of porphyria other than PCT.",
"   </p>",
"   <p>",
"    Hypertrichosis and hyperpigmentation also improve gradually. Pseudosclerodermatous skin changes improve in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/96\">",
"     96",
"    </a>",
"    ]. Improvement in liver function and histology are reported, but are inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/95\">",
"     95",
"    </a>",
"    ], reflecting that some associated susceptibility factors can cause liver damage. A predominance of highly carboxylated porphyrins may persist after total plasma and urine porphyrin levels become normal, but eventually a normal pattern with a predominance of coproporphyrin returns [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is generally not necessary to continue phlebotomies after achieving remission. Relapses may occur, especially in patients who resume excess alcohol intake, but the frequency and relationship to other susceptibility factors are unclear. Relapse rates of 10 to 50 percent within two to four years of treatment have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/95\">",
"     95",
"    </a>",
"    ]. It is prudent to measure plasma or urine porphyrins, perhaps annually, so that a relapse can be detected and treated early. Serum ferritin should be monitored in patients with HFE genotypes",
"    <span class=\"nowrap\">",
"     C282Y/C282Y",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     C282Y/H63D,",
"    </span>",
"    and these patients should probably undergo periodic phlebotomies to maintain a serum ferritin below 50",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    as currently recommended for hereditary hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of hereditary hemochromatosis\", section on 'Maintenance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Phlebotomy may be difficult in patients with poor venous access, anemia, cardiac disease, and other medical conditions. Removal of iron by the use of iron chelating agents is a potential option, but is a less efficient method for iron reduction than phlebotomy. (See",
"    <a class=\"local\" href=\"#H11620976\">",
"     'Iron chelation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Administration of erythropoietin can correct anemia and support the ability of patients with PCT and end-stage renal disease to tolerate repeated phlebotomies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/77,105\">",
"     77,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527460\">",
"    <span class=\"h3\">",
"     Hydroxychloroquine or chloroquine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low-dose regimen of the 4-aminoquinoline antimalarials",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    is an effective treatment of PCT and a suitable alternative when phlebotomies are difficult or poorly tolerated. These drugs are concentrated in the liver, particularly in lysosomes, and mobilize porphyrins from the liver by a poorly defined mechanism. Hydroxychloroquine may have less potential for adverse effects than chloroquine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H7#H7\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These drugs cause substantial adverse effects when given to patients with PCT in doses approaching those used for other conditions, including an acute hepatotoxic reaction with an increase in plasma transaminases and an increase in plasma porphyrins and worsening of photosensitivity. Over time, the excess porphyrins are excreted in the urine, followed by remission of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/106\">",
"     106",
"    </a>",
"    ]. In an attempt to avoid these complications, low-dose regimens of these agents were devised and found to be effective. The recommended regimen is 100 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    taken orally twice weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/20,107-110\">",
"     20,107-110",
"    </a>",
"    ]. Mild transaminase and porphyrin elevations may occur initially, but are usually not accompanied by symptoms. In a prospective study, low dose hydroxychloroquine in a dose of 100 mg twice a week was found to be as effective, in terms of time to remission, and as safe as phlebotomy in the treatment of PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retinopathy is a potential dose-related risk with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    ). Although this is unlikely to occur with this low-dose regimen, ophthalmological examination before and during treatment has been recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H17#H17\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Ocular health'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of treatment is not established, but most experts continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    until plasma or urine porphyrin levels have been normal for at least several months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/107\">",
"     107",
"    </a>",
"    ]. Relapse rates after these treatments have not been directly compared.",
"   </p>",
"   <p>",
"    Contraindications to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    ) include pregnancy; lactation; advanced liver disease; recent and continued use of alcohol or hepatotoxic drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    or valproic acid; glucose-6-phosphate dehydrogenase deficiency; psoriasis; and retinal disease. Chloroquine has been reported to be ineffective in PCT patients with C282Y homozygous hereditary hemochromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/112\">",
"     112",
"    </a>",
"    ]; this observation presumably applies to hydroxychloroquine as well. Because iron itself can cause organ damage and these antimalarial agents do not reduce iron overload, patients with substantial iron overload should be treated with phlebotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of hereditary hemochromatosis\", section on 'Phlebotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These drugs should not be used to treat PCT in patients with end-stage renal disease, because mobilized porphyrins are poorly dialyzed. Phlebotomy supported by administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    is clearly preferred in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11620976\">",
"    <span class=\"h3\">",
"     Iron chelation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral or subcutaneous iron chelators are much less efficient in removing iron than phlebotomies, and are not considered as alternatives to phlebotomy or low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , which are comparable in terms of time to remission [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/101,111,113,114\">",
"     101,111,113,114",
"    </a>",
"    ]. Iron chelation might be considered in rare instances when both phlebotomy and low-dose hydroxychloroquine are contraindicated, but experience with iron chelation for PCT is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subcutaneous iron chelators have been used to treat PCT, but are challenging to administer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/101,115,116\">",
"     101,115,116",
"    </a>",
"    ]. A small randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    with desferrioxamine in 40 patients with PCT showed that the patients treated with hydroxychloroquine responded more rapidly than the patients treated with desferrioxamine (mean time to resolution of clinical symptoms six months with hydroxychloroquine and 12 months with desferrioxamine) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/117\">",
"     117",
"    </a>",
"    ]. In a small pilot study of treatment of PCT with the oral iron chelator",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    , decreases in ferritin and porphyrin levels (41 and 53 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/114\">",
"     114",
"    </a>",
"    ] were less than are reported with phlebotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527467\">",
"    <span class=\"h3\">",
"     Other treatment options",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence for efficacy of other treatments, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/118\">",
"     118",
"    </a>",
"    ], plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/119\">",
"     119",
"    </a>",
"    ], vitamin E [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/120\">",
"     120",
"    </a>",
"    ], N-acetylcysteine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/121\">",
"     121",
"    </a>",
"    ], anastrazole [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/122\">",
"     122",
"    </a>",
"    ], or urinary alkalization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/123\">",
"     123",
"    </a>",
"    ]. These should",
"    <strong>",
"     not",
"    </strong>",
"    be considered as alternatives to phlebotomy or low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527474\">",
"    <span class=\"h3\">",
"     Treatment of hepatitis C and HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with both PCT and hepatitis C should first be treated for PCT, which is usually more symptomatic and more likely to respond to therapy, usually within a few months. Treatment for hepatitis C is more prolonged and can be considered at a later time. Repeated phlebotomy may not be feasible during treatment with interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , which often causes anemia. Treatment of HCV after PCT is in remission is likely to prevent recurrence of PCT. However, since multiple susceptibility factors are found in individual patients, these may contribute to recurrence even in the absence of HCV.",
"   </p>",
"   <p>",
"    When PCT first appears or relapses during treatment of hepatitis C, low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    is an option, although experience with this drug is limited in this setting. Response to treatment of hepatitis C with interferon is reportedly impaired in patients with a history of PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/124\">",
"     124",
"    </a>",
"    ], but our limited unpublished experience suggests that such individuals respond as often to combined interferon-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    as those who have never had porphyria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30421?source=see_link&amp;anchor=H8#H8\">",
"     \"Porphyria cutanea tarda and hepatitis C virus infection\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PCT is",
"    <strong>",
"     not",
"    </strong>",
"    a reason to delay treatment for HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527481\">",
"    <span class=\"h3\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with familial (type 2) PCT usually have no family history of the disease because penetrance is low. Heterozygous carriers of UROD mutations who are asymptomatic may have increased urinary porphyrins, which can be monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/125\">",
"     125",
"    </a>",
"    ], and they can be advised to avoid additional susceptibility factors that might lead to development of overt disease, such as heavy alcohol use, smoking and perhaps oral estrogens. (See",
"    <a class=\"local\" href=\"#H4527395\">",
"     'Susceptibility factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients without UROD mutations are classified as type 1, or as type 3 if another family member is affected. Type 3 disease is rare and may be due in part to HFE mutations or other genetic factors that may increase susceptibility for developing PCT in relatives, or perhaps to shared environmental influences. (See",
"    <a class=\"local\" href=\"#H4530131\">",
"     'Genetic susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527488\">",
"    <span class=\"h1\">",
"     HEPATOERYTHROPOIETIC PORPHYRIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4530260\">",
"    <span class=\"h2\">",
"     Definition and prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatoerythropoietic porphyria (HEP) is a rare disorder (approximately 40 cases have been documented) that is the homozygous or compound heterozygous form of familial porphyria cutanea tarda (PCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. Cutaneous photosensitivity usually begins in childhood and is usually more severe than in PCT. Disease onset is usually prior to two years of age, although onset in adulthood has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/27,128\">",
"     27,128",
"    </a>",
"    ]. The disease occurs worldwide and in both males and females.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527497\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin photosensitivity is manifested early in life as blistering, scarring, hypertrichosis and pigment changes, resembling congenital erythropoietic porphyria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5801?source=see_link\">",
"     \"Congenital erythropoietic porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features in milder and later onset cases may be indistinguishable from PCT. Bacterial infections and scarring may be disfiguring. Mild anemia due at least in part to hemolysis is common, and may be accompanied by hepatosplenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527504\">",
"    <span class=\"h2\">",
"     Etiology and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HEP is due to markedly reduced activity of hepatic uroporphyrinogen decarboxylase (UROD) to usually less than 20 percent of normal as measured in erythrocytes. Patients are either homozygous for one UROD mutation or compound heterozygous for a different UROD mutation inherited from each parent. At least one of the inherited mutations must express some UROD enzymatic activity, since a null mutation would be lethal in the homozygous state [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, null mutations are much less common in HEP than in heterozygotes with familial (type 2) PCT.",
"   </p>",
"   <p>",
"    HEP is primarily hepatic, although a marked increase in erythrocyte zinc protoporphyrin indicates that the heme biosynthetic pathway in the bone marrow is also affected. The excess zinc protoporphyrin in erythrocytes is probably formed from pathway intermediates that accumulate during hemoglobin synthesis and are later metabolized to protoporphyrin, and then complexed with zinc [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    UROD activity is markedly reduced in HEP, which is sufficient to lead to accumulation of highly carboxylated porphyrinogens and porphyrins in liver and possibly other tissues. The hepatic UROD inhibitor and susceptibility factors that are important in PCT generally do not have a significant role in HEP. (See",
"    <a class=\"local\" href=\"#H4530208\">",
"     'Decreased hepatic UROD activity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527511\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in PCT, highly carboxylated porphyrins and isocoproporphyrins are increased in HEP especially in liver, plasma, urine, and feces. Erythrocyte zinc protoporphyrin is markedly increased. Porphyrin precursors (ie, delta",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    and porphobilinogen) are normal.",
"   </p>",
"   <p>",
"    Hematological abnormalities may include mild, normocytic and normochromic anemia due in part to hemolysis. Mild and nonspecific abnormalities in liver function and histology are common, usually without siderosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527518\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible presence of HEP should be considered in children with chronic, blistering photosensitivity. HEP is differentiated from congenital erythropoietic porphyria by the patterns of individual porphyrins in plasma, urine, and erythrocytes, and by a marked reduction in erythrocyte UROD activity (",
"    <a class=\"graphic graphic_table graphicRef80601 \" href=\"UTD.htm?31/63/32765\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4527439\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Porphyrin patterns in HEP closely resemble those seen in PCT, but a marked elevation in erythrocyte protoporphyrin (mostly zinc protoporphyrin) is characteristic of HEP, and erythrocyte UROD activity is more reduced (usually to less than 20 percent of normal) than in type 2 (familial) PCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/129-132\">",
"     129-132",
"    </a>",
"    ]. The diagnosis of HEP should be confirmed by molecular studies that demonstrate mutations affecting",
"    <strong>",
"     both",
"    </strong>",
"    UROD alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/126,127,129\">",
"     126,127,129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4527525\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protection from sunlight is especially important in patients with HEP and is the only recognized treatment for this disorder. With such management, the overall prognosis is good, but fingers and facial features may be disfigured in severe cases. Identification of UROD mutations in a previous case in a family can enable genetic counseling and prenatal diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since excess iron and hepatic siderosis are not features of HEP, treatments for PCT, such as phlebotomy, are usually not helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/27,126\">",
"     27,126",
"    </a>",
"    ]. Other treatments that have been considered include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      was apparently useful in one case [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/126\">",
"       126",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recombinant erythropoietin may be useful for treatment of anemia if not due to increased red cell destruction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/128\">",
"       128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Because the enzyme deficiency in liver is the most important cause of HEP, bone marrow transplantation is not useful [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral charcoal, which can bind porphyrins in the gastrointestinal tract [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/134\">",
"       134",
"      </a>",
"      ], was helpful in a case of severe disease associated with dyserythropoiesis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/135\">",
"       135",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Retrovirus-mediated gene transfer can correct porphyria in cell lines from HEP patients, suggesting that gene replacement therapy may be effective in the future [",
"      <a class=\"abstract\" href=\"UTD.htm?27/50/28458/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H962869723\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porphyria cutanea tarda (PCT) and hepatoerythropoietic porphyria (HEP) are porphyric conditions due to deficient activity of hepatic uroporphyrinogen decarboxylase (UROD), the fifth enzyme in the heme biosynthetic pathway. Both are associated with chronic blistering photosensitivity. (See",
"    <a class=\"local\" href=\"#H4527379\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCT, the most common human porphyria, is an iron-related disease that usually presents in mid or late life.",
"     </li>",
"     <li>",
"      HEP is the autosomal recessive form of familial PCT. This very rare disease is associated with a more severe deficiency of UROD, and usually presents in childhood with features that resemble congenital erythropoietic porphyria (CEP).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H962869792\">",
"    <span class=\"h2\">",
"     Suspecting the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blistering skin lesions on the backs of the hands and other sun exposed areas of skin should suggest this disease. Most patients with PCT will have multiple inherited and acquired &ldquo;susceptibility factors&rdquo; for this disorder, including smoking, excess use of alcohol, hepatitis C virus or HIV infection, estrogen use, and HFE mutations. Some are heterozygous for UROD mutations. (See",
"    <a class=\"local\" href=\"#H4527395\">",
"     'Susceptibility factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H962869844\">",
"    <span class=\"h2\">",
"     Confirming the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PCT is made by demonstrating the increased presence of highly carboxylated porphyrins in plasma or urine, usually with a predominance of uroporphyrin and heptacarboxyl porphyrin (",
"    <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"     table 2",
"    </a>",
"    ). The familial form of PCT will demonstrate approximately half-normal UROD activity in all tissues from the time of birth, with a more severe deficiency developing in the liver when the disease becomes active. Patients with HEP will have similar laboratory findings and will also demonstrate markedly increased levels of erythrocyte zinc protoporphyrin along with erythrocyte UROD activity usually to less than 20 percent of normal. (See",
"    <a class=\"local\" href=\"#H4527439\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H962869866\">",
"    <span class=\"h2\">",
"     Treatment of PCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients with symptomatic PCT be treated with either repeated phlebotomies to reduce the serum ferritin to a target level of about 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or with a low-dose regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (100 mg twice weekly), which achieves remission by mobilizing the accumulated porphyrins from the liver (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). Phlebotomy is preferred at most centers. (See",
"    <a class=\"local\" href=\"#H4527446\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H962869897\">",
"    <span class=\"h2\">",
"     Treatment of HEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than protecting against exposure to sunlight, there is no effective treatment for this disorder. Identification of UROD mutations in a previous case in a family can enable genetic counseling and prenatal diagnosis.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Elder GH. Porphyria cutanea tarda and related disorders. In: The Porphyrin Handbook, Kadish K, Smith K, Guilard R (Eds), Elsevier Science, San Diego 2003. Vol 14, p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/2\">",
"      Phillips JD, Bergonia HA, Reilly CA, et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A 2007; 104:5079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/3\">",
"      Elder GH, Smith SG, Herrero C, et al. Hepatoerythropoietic porphyria: a new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda? Lancet 1981; 1:916.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: The Metabolic and Molecular Basis of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, et al. (Eds), McGraw-Hill, New York 2001. p.2991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/5\">",
"      Gunther H. Die h&auml;matoporphyrie. Dtsh Arch Klin Med 1911; 105:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/6\">",
"      Waldenstrom J. Studien &uuml;ber porphyrie. Acta Med Scand 1937; Suppl82.",
"     </a>",
"    </li>",
"    <li>",
"     Harber LC, Bickers DR. Photosensitivity diseases: principles of diagnosis and treatment, WB Saunders, Philadelphia 1981. p.189.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/8\">",
"      Brady JJ, Jackson HA, Roberts AG, et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol 2000; 115:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/9\">",
"      Grossman ME, Bickers DR, Poh-Fitzpatrick MB, et al. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am J Med 1979; 67:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/10\">",
"      Mascaro JM. The porphyrias: a brief overview based on 25 years of experience (1969-1994) by the Department of Dermatology of the Hospital Clinic and Faculty of Medicine of Barcelona, Spain. J Dermatol 1995; 22:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/11\">",
"      Stevens HP, Ostlere LS, Black CM, Rustin MH. Generalized morphoea secondary to porphyria cutanea tarda. Br J Dermatol 1993; 129:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/12\">",
"      Magnus IA. Cutaneous porphyria. Clin Haematol 1980; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/13\">",
"      Lim HW, Poh-Fitzpatrick MB, Gigli I. Activation of the complement system in patients with porphyrias after irradiation in vivo. J Clin Invest 1984; 74:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/14\">",
"      Lan&ccedil;oni G, Ravinal RC, Costa RS, Roselino AM. Mast cells and transforming growth factor-beta expression: a possible relationship in the development of porphyria cutanea tarda skin lesions. Int J Dermatol 2008; 47:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/15\">",
"      Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol 1992; 19:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/16\">",
"      Scholnick PL, Epstein J, Marver HS. The molecular basis of the action of chloroquine in porphyria cutanea tarda. J Invest Dermatol 1973; 61:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/17\">",
"      Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/18\">",
"      Fakan F, Chlumsk&aacute; A. Demonstration of needle-shaped hepatic inclusions in porphyria cutanea tarda using the ferric ferricyanide reduction test. Virchows Arch A Pathol Anat Histopathol 1987; 411:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/19\">",
"      Cort&eacute;s JM, Oliva H, Paradinas FJ, Hernandez-Gu&iacute;o C. The pathology of the liver in porphyria cutanea tarda. Histopathology 1980; 4:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/20\">",
"      Chlumska A, Chlumsky J, Malina L. Liver changes in porphyria cutanea tarda patients treated with chloroquine. Br J Dermatol 1980; 102:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/21\">",
"      Kordac V. Frequency of occurrence of hepatocellular carcinoma in patients with porphyria cutanea tarda in long-term follow-up. Neoplasma 1972; 19:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/22\">",
"      Linet MS, Gridley G, Nyr&eacute;n O, et al. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol 1999; 149:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/23\">",
"      Jalil S, Grady JJ, Lee C, Anderson KE. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol 2010; 8:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/24\">",
"      M&eacute;ndez M, Poblete-Guti&eacute;rrez P, Garc&iacute;a-Bravo M, et al. Molecular heterogeneity of familial porphyria cutanea tarda in Spain: characterization of 10 novel mutations in the UROD gene. Br J Dermatol 2007; 157:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/25\">",
"      Garey JR, Hansen JL, Harrison LM, et al. A point mutation in the coding region of uroporphyrinogen decarboxylase associated with familial porphyria cutanea tarda. Blood 1989; 73:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/26\">",
"      McManus JF, Begley CG, Sassa S, Ratnaike S. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria. Blood 1996; 88:3589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/27\">",
"      Moran-Jimenez MJ, Ged C, Romana M, et al. Uroporphyrinogen decarboxylase: complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria. Am J Hum Genet 1996; 58:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/28\">",
"      Mendez M, Sorkin L, Rossetti MV, et al. Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles. Am J Hum Genet 1998; 63:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/29\">",
"      Phillips JD, Whitby FG, Stadtmueller BM, et al. Two novel uroporphyrinogen decarboxylase (URO-D) mutations causing hepatoerythropoietic porphyria (HEP). Transl Res 2007; 149:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/30\">",
"      Badenas C, To-Figueras J, Phillips JD, et al. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet 2009; 75:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/31\">",
"      Gorman N, Zaharia A, Trask HS, et al. Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda. Hepatology 2007; 46:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/32\">",
"      Nakano K, Ishizuka M, Sakamoto KQ, Fujita S. Absolute requirement for iron in the development of chemically induced uroporphyria in mice treated with 3-methylcholanthrene and 5-aminolevulinate. Biometals 2009; 22:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/33\">",
"      Turnbull A, Baker H, Vernon-Roberts B, Magnus IA. Iron metabolism in porphyria cutanea tarda and in erythropoietic protoporphyria. Q J Med 1973; 42:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/34\">",
"      Bygum A, Brandrup F. Iron overload in porphyria cutanea tarda. Br J Dermatol 2000; 143:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/35\">",
"      Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003; 30:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/36\">",
"      Lundvall O, Weinfeld A, Lundin P. Iron storage in porphyria cutanea tarda. Acta Med Scand 1970; 1-2:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/37\">",
"      Elder GH. Porphyrin metabolism in porphyria cutanea tarda. Semin Hematol 1977; 14:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/38\">",
"      Sampietro M, Fiorelli G, Fargion S. Iron overload in porphyria cutanea tarda. Haematologica 1999; 84:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/39\">",
"      Dereure O, Jumez N, Bessis D, et al. Measurement of liver iron content by magnetic resonance imaging in 20 patients with overt porphyria cutanea tarda before phlebotomy therapy: a prospective study. Acta Derm Venereol 2008; 88:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/40\">",
"      Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000; 95:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/41\">",
"      Stuart KA, Busfield F, Jazwinska EC, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol 1998; 28:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/42\">",
"      Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007; 46:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/43\">",
"      Ajioka RS, Phillips JD, Weiss RB, et al. Down-regulation of hepcidin in porphyria cutanea tarda. Blood 2008; 112:4723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/44\">",
"      St&ouml;lzel U, K&ouml;stler E, Koszka C, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995; 21:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/45\">",
"      HALLEN J, KROOK H. Follow-up studies on an unselected ten-year material of 360 patients with liver cirrhosis in one community. Acta Med Scand 1963; 173:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/46\">",
"      Harrison-Findik DD, Klein E, Crist C, et al. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 2007; 46:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/47\">",
"      Ohtake T, Saito H, Hosoki Y, et al. Hepcidin is down-regulated in alcohol loading. Alcohol Clin Exp Res 2007; 31:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/48\">",
"      Sinclair PR, Gorman N, Tsyrlov IB, et al. Uroporphyrinogen oxidation catalyzed by human cytochromes P450. Drug Metab Dispos 1998; 26:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/49\">",
"      Fontanellas A, Mart&iacute;nez-Fresno M, Garrido-Astray MC, et al. Smoking but not homozygosity for CYP1A2 g-163A allelic variant leads to earlier disease onset in patients with sporadic porphyria cutanea tarda. Exp Dermatol 2010; 19:e326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/50\">",
"      Christiansen L, Bygum A, Jensen A, et al. Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum Genet 2000; 107:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/51\">",
"      Wickliffe JK, Abdel-Rahman SZ, Lee C, et al. CYP1A2*1F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med 2011; 17:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/52\">",
"      Fargion S, Piperno A, Cappellini MD, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992; 16:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/53\">",
"      Kristiansen MG, L&oslash;chen ML, Gutteberg TJ, et al. Hepatitis C virus infection was not found in patients with sporadic porphyria cutanea tarda, membranoproliferative glomerulonephritis or membranous glomerulonephritis in Northern Norway. Scand J Gastroenterol 2009; 44:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/54\">",
"      DeCastro M, S&aacute;nchez J, Herrera JF, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/55\">",
"      Navas S, Bosch O, Castillo I, et al. Porphyria cutanea tarda and hepatitis C and B viruses infection: a retrospective study. Hepatology 1995; 21:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/56\">",
"      Lamoril J, Andant C, Bogard C, et al. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 1998; 27:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/57\">",
"      Korenaga M, Okuda M, Otani K, et al. Mitochondrial dysfunction in hepatitis C. J Clin Gastroenterol 2005; 39:S162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/58\">",
"      Miura K, Taura K, Kodama Y, et al. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/59\">",
"      Wissel PS, Sordillo P, Anderson KE, et al. Porphyria cutanea tarda associated with the acquired immune deficiency syndrome. Am J Hematol 1987; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/60\">",
"      Drobacheff C, Derancourt C, Van Landuyt H, et al. Porphyria cutanea tarda associated with human immunodeficiency virus infection. Eur J Dermatol 1998; 8:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/61\">",
"      Castanet J, Lacour JP, Bodokh J, et al. Porphyria cutanea tarda in association with human immunodeficiency virus infection: it is related to hepatitis C virus infection? Arch Dermatol 1994; 130:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/62\">",
"      Mansourati FF, Stone VE, Mayer KH. Porphyria cutanea tarda and HIV/AIDS: a review of pathogenesis, clinical manifestations and management. Int J STD AIDS 1999; 10:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/63\">",
"      Goerz G, Hammer G. Porphyria cutanea tarda and pregnancy. Dermatologica 1983; 166:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/64\">",
"      Egger NG, Goeger DE, Payne DA, et al. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002; 47:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/65\">",
"      Rajka G. Pregnancy and porphyria cutanea tarda. Acta Derm Venereol 1984; 64:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/66\">",
"      Roenigk HH Jr, Gottlob ME. Estrogen-induced porphyria cutanea tarda. Report of three cases. Arch Dermatol 1970; 102:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/67\">",
"      Wang MY, Liehr JG. Identification of fatty acid hydroperoxide cofactors in the cytochrome P450-mediated oxidation of estrogens to quinone metabolites. Role and balance of lipid peroxides during estrogen-induced carcinogenesis. J Biol Chem 1994; 269:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/68\">",
"      SCHMID R. Acquired porphyria. JAMA 1963; 183:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/69\">",
"      CAN C, NIGOGOSYAN G. Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. Report of 348 cases caused by this fungicide. JAMA 1963; 183:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/70\">",
"      Jones RE, Chelsky M. Further discussion concerning porphyria cutanea tarda and TCDD exposure. Arch Environ Health 1986; 41:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/71\">",
"      Collins AG, Nichol AW, Elsbury S. Porphyria cutanea tarda and agricultural pesticides. Australas J Dermatol 1982; 23:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/72\">",
"      Bleakley P, Nichol AW, Collins AG. Diazinon and porphyria cutanea tarda. Med J Aust 1979; 1:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/73\">",
"      Gibson GE, McEvoy MT. Coexistence of lupus erythematosus and porphyria cutanea tarda in fifteen patients. J Am Acad Dermatol 1998; 38:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/74\">",
"      Rossmann-Ringdahl I, Olsson R. Porphyria cutanea tarda in a Swedish population: risk factors and complications. Acta Derm Venereol 2005; 85:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/75\">",
"      Lee SC, Yun SJ, Lee JB, et al. A case of porphyria cutanea tarda in association with idiopathic myelofibrosis and CREST syndrome. Br J Dermatol 2001; 144:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/76\">",
"      Seubert S, Seubert A, Rumpf KW, Kiffe H. A porphyria cutanea tarda-like distribution pattern of porphyrins in plasma, hemodialysate, hemofiltrate, and urine of patients on chronic hemodialysis. J Invest Dermatol 1985; 85:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/77\">",
"      Anderson KE, Goeger DE, Carson RW, et al. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med 1990; 322:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/78\">",
"      de Verneuil H, Sassa S, Kappas A. Purification and properties of uroporphyrinogen decarboxylase from human erythrocytes. A single enzyme catalyzing the four sequential decarboxylations of uroporphyrinogens I and III. J Biol Chem 1983; 258:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/79\">",
"      Jackson AH, Sancovich HA, Ferramola AM, et al. Macrocyclic intermediates in the biosynthesis of porphyrins. Philos Trans R Soc Lond B Biol Sci 1976; 273:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/80\">",
"      Poh-Fitzpatrick MB. A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol 1980; 116:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/81\">",
"      Deacon AC, Elder GH. ACP Best Practice No 165: front line tests for the investigation of suspected porphyria. J Clin Pathol 2001; 54:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/82\">",
"      Aarsand AK, Boman H, Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem 2009; 55:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/83\">",
"      Thunell S, Harper P. Porphyrins, porphyrin metabolism, porphyrias. III. Diagnosis, care and monitoring in porphyria cutanea tarda--suggestions for a handling programme. Scand J Clin Lab Invest 2000; 60:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/84\">",
"      Sarkany RP. The management of porphyria cutanea tarda. Clin Exp Dermatol 2001; 26:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/85\">",
"      Hindmarsh JT, Oliveras L, Greenway DC. Plasma porphyrins in the porphyrias. Clin Chem 1999; 45:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/86\">",
"      O'Reilly K, Snape J, Moore MR. Porphyria cutanea tarda resulting from primary hepatocellular carcinoma. Clin Exp Dermatol 1988; 13:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/87\">",
"      Ochiai T, Morishima T, Kondo M. Symptomatic porphyria secondary to hepatocellular carcinoma. Br J Dermatol 1997; 136:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/88\">",
"      Anderson KE. Pseudoporphyria versus porphyria cutanea tarda. J Pediatr 1993; 123:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/89\">",
"      Bulaj ZJ, Franklin MR, Phillips JD, et al. Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda. J Lab Clin Med 2000; 136:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/90\">",
"      Millar JW. Rifampicin-induced porphyria cutanea tarda. Br J Dis Chest 1980; 74:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/91\">",
"      Ramsay CA, Magnus IA, Turnbull A, Baker H. The treatment of porphyria cutanea tarda by venesection. Q J Med 1974; 43:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/92\">",
"      Ratnaike S, Blake D, Campbell D, et al. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection. Australas J Dermatol 1988; 29:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/93\">",
"      Epstein JH, Redeker AG. Porphyria cutanea tarda. A study of the effect of phlebotomy. N Engl J Med 1968; 279:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/94\">",
"      Lundvall O. The effect of phlebotomy therapy in porphyria cutanea tarda. Its relation to the phlebotomy-induced reduction of iron stores. Acta Med Scand 1971; 189:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/95\">",
"      Chlumsk&yacute; J, Malina L, Chlumsk&aacute; A. The effect of venesection therapy on liver tissue in porphyria cutanea tarda. Acta Hepatogastroenterol (Stuttg) 1973; 20:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/96\">",
"      Ippen H. Treatment of porphyria cutanea tarda by phlebotomy. Semin Hematol 1977; 14:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/97\">",
"      Enr&iacute;quez de Salamanca R, Rico R, Pe&ntilde;a ML, et al. Patterns of porphyrin excretion in porphyria cutanea tarda under venesection treatment. Int J Biochem 1980; 12:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/98\">",
"      Di Padova C, Marchesi L, Cainelli T, et al. Effects of phlebotomy on urinary porphyrin pattern and liver histology in patients with porphyria cutanea tarda. Am J Med Sci 1983; 285:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/99\">",
"      Adjarov D, Donov M, Ivanov E, Naidenova E. Phlebotomy treatment in porphyria cutanea tarda combined with beta-thalassaemia. Dermatologica 1984; 169:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/100\">",
"      Rocchi E, Gibertini P, Cassanelli M, et al. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab Clin Med 1986; 107:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/101\">",
"      Rocchi E, Gibertini P, Cassanelli M, et al. Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion. Br J Dermatol 1986; 114:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/102\">",
"      Enr&iacute;quez de Salamanca R, Mingo D, Chinarro S, et al. Patterns of porphyrin-excretion in female estrogen-induced porphyria cutanea tarda. Arch Dermatol Res 1982; 274:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/103\">",
"      Epstein JH, Redeker AG. Porphyria cutanea tarda symptomatica (PCT-S). A study of the effect of phlebotomy therapy. Arch Dermatol 1965; 92:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/104\">",
"      Tavill AS, American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association. Diagnosis and management of hemochromatosis. Hepatology 2001; 33:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/105\">",
"      Shieh S, Cohen JL, Lim HW. Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review. J Am Acad Dermatol 2000; 42:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/106\">",
"      SWEENEY GD, SAUNDERS SJ, DOWDLE EB, EALES L. EFFECTS OF CHLOROQUINE ON PATIENTS WITH CUTANEOUS PORPHYRIA OF THE \"SYMPTOMATIC\" TYPE. Br Med J 1965; 1:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/107\">",
"      Ashton RE, Hawk JL, Magnus IA. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Br J Dermatol 1984; 111:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/108\">",
"      Freesemann A, Frank M, Sieg I, Doss MO. Treatment of porphyria cutanea tarda by the effect of chloroquine on the liver. Skin Pharmacol 1995; 8:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/109\">",
"      Wolff C, Armas R, Krause P, et al. [Treatment of porphyria cutanea tarda with chloroquine and its effect on associated liver disease: retrospective analysis]. Rev Med Chil 1996; 124:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/110\">",
"      Kordac V, Papezov&aacute; R, Semr&aacute;dov&aacute; M. Chloroquine in the treatment of porphyria cutanea tarda. N Engl J Med 1977; 296:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/111\">",
"      Singal AK, Kormos-Hallberg C, Lee C, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol 2012; 10:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/112\">",
"      St&ouml;lzel U, K&ouml;stler E, Schuppan D, et al. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003; 139:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/113\">",
"      Rocchi E, Cassanelli M, Ventura E. High weekly intravenous doses of desferrioxamine in porphyria cutanea tarda. Br J Dermatol 1987; 117:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/114\">",
"      Pandya AG, Nezafati KA, Ashe-Randolph M, Yalamanchili R. Deferasirox for porphyria cutanea tarda: a pilot study. Arch Dermatol 2012; 148:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/115\">",
"      Gibertini P, Rocchi E, Cassanelli M, et al. Advances in the treatment of porphyria cutanea tarda. Effectiveness of slow subcutaneous desferrioxamine infusion. Liver 1984; 4:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/116\">",
"      Rocchi E, Cassanelli M, Borghi A, et al. Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda. Dermatologica 1991; 182:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/117\">",
"      Marchesi L, Di Padova C, Cainelli T, et al. A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients. Photodermatol 1984; 1:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/118\">",
"      Monastirli A, Georgiou S, Bolsen K, et al. Treatment of porphyria cutanea tarda with oral thalidomide. Skin Pharmacol Appl Skin Physiol 1999; 12:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/119\">",
"      Miyauchi S, Shiraishi S, Miki Y. Small volume plasmapheresis in the management of porphyria cutanea tarda. Arch Dermatol 1983; 119:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/120\">",
"      Ayres S Jr, Mihan R. Porphyria cutanea tarda: response to vitamin E. A review and two case reports. Cutis 1978; 22:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/121\">",
"      Binet H, Simonart T, Van Vooren JP, et al. Porphyria cutanea tarda in a human immunodeficiency virus-infected patient: treatment with N-acetyl-cysteine. Int J Dermatol 1998; 37:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/122\">",
"      Bertoli LF, Barton JC. Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer. Clin Breast Cancer 2007; 7:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/123\">",
"      Perry HO, Mullanax MG, Wiegand SE. Metabolic alkalinization therapy in porphyria cutanea tarda. Arch Dermatol 1970; 102:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/124\">",
"      Fern&aacute;ndez I, Castellano G, de Salamanca RE, et al. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol 2003; 38:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/125\">",
"      Enriquez de Salamanca R, Olmos A, Pe&ntilde;a ML, et al. The genetic basis of porphyria cutanea tarda. Arch Dermatol Res 1985; 277:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/126\">",
"      Meguro K, Fujita H, Ishida N, et al. Molecular defects of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria. J Invest Dermatol 1994; 102:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/127\">",
"      Cantatore-Francis JL, Cohen-Pfeffer J, Balwani M, et al. Hepatoerythropoietic porphyria misdiagnosed as child abuse: cutaneous, arthritic, and hematologic manifestations in siblings with a novel UROD mutation. Arch Dermatol 2010; 146:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/128\">",
"      Horina JH, Wolf P. Epoetin for severe anemia in hepatoerythropoietic porphyria. N Engl J Med 2000; 342:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/129\">",
"      Day RS, Strauss PC. Severe cutaneous porphyria in a 12-year-old boy: hepatoerythropoietic or symptomatic porphyria? Arch Dermatol 1982; 118:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/130\">",
"      Lim HW, Poh-Fitzpatrick MB. Hepatoerythropoietic porphyria: a variant of childhood-onset porphyria cutanea tarda. Porphyrin profiles and enzymatic studies of two cases in a family. J Am Acad Dermatol 1984; 11:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/131\">",
"      Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol 2006; 135:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/132\">",
"      Boudgh&egrave;ne-Stambouli O, M&eacute;rad-Boudia A. [Hepato-erythropoietic porphyria]. Ann Dermatol Venereol 1995; 122:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/133\">",
"      Ged C, Ozalla D, Herrero C, et al. Description of a new mutation in hepatoerythropoietic porphyria and prenatal exclusion of a homozygous fetus. Arch Dermatol 2002; 138:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/134\">",
"      Tishler PV, Winston SH. Rapid improvement in the chemical pathology of congenital erythropoietic porphyria with treatment with superactivated charcoal. Methods Find Exp Clin Pharmacol 1990; 12:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/135\">",
"      Pimstone NR, Gandhi SN, Mukerji SK. Therapeutic efficacy of oral charcoal in congenital erythropoietic porphyria. N Engl J Med 1987; 316:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/50/28458/abstract/136\">",
"      Christiansen L, Ged C, Hombrados I, et al. Screening for mutations in the uroporphyrinogen decarboxylase gene using denaturing gradient gel electrophoresis. Identification and characterization of six novel mutations associated with familial PCT. Hum Mutat 1999; 14:222.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7108 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28458=[""].join("\n");
var outline_f27_50_28458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H962869723\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4527356\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3066774\">",
"      PORPHYRIA CUTANEA TARDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4530116\">",
"      Definition and history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527372\">",
"      Prevalence and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527379\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530124\">",
"      - Skin findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4527388\">",
"      - Hepatic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527395\">",
"      Susceptibility factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530131\">",
"      - Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530138\">",
"      - Iron",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530145\">",
"      - Alcohol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530152\">",
"      - Smoking and cytochrome P450 enzymes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530159\">",
"      - Hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530166\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530173\">",
"      - Estrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530180\">",
"      - Chemical exposures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530187\">",
"      - Other associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530201\">",
"      - End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527402\">",
"      Etiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4530208\">",
"      - Decreased hepatic UROD activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4527411\">",
"      - Porphyrin accumulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527425\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527432\">",
"      Liver findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527439\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H962869007\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527446\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4527453\">",
"      - Repeated phlebotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4527460\">",
"      - Hydroxychloroquine or chloroquine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11620976\">",
"      - Iron chelation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4527467\">",
"      - Other treatment options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4527474\">",
"      - Treatment of hepatitis C and HIV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4527481\">",
"      - Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4527488\">",
"      HEPATOERYTHROPOIETIC PORPHYRIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4530260\">",
"      Definition and prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527497\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527504\">",
"      Etiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527511\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527518\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4527525\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H962869723\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H962869792\">",
"      Suspecting the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H962869844\">",
"      Confirming the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H962869866\">",
"      Treatment of PCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H962869897\">",
"      Treatment of HEP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7108\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7108|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25077\" title=\"figure 1\">",
"      Heme synthesis and porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/31/23037\" title=\"figure 2\">",
"      Porphyria oxidation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7108|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/30/13794\" title=\"picture 1\">",
"      Porphyria cutanea tarda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14066\" title=\"picture 2\">",
"      Porphyria cutanea tarda 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/4/10304\" title=\"picture 3\">",
"      Porphyria cutanea tarda 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7108|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/9/155\" title=\"table 1\">",
"      Heme pathway enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/23/4477\" title=\"table 2\">",
"      Excretion patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/63/32765\" title=\"table 3\">",
"      Classification porphyrias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5801?source=related_link\">",
"      Congenital erythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=related_link\">",
"      Etiology and pathogenesis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30421?source=related_link\">",
"      Porphyria cutanea tarda and hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21111?source=related_link\">",
"      Pseudoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_50_28459="Meta anal chemo plus RT NPC";
var content_f27_50_28459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Meta-analysis of chemoradiotherapy compared to radiotherapy alone for stage III/IV nasopharyngeal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Chemotherapy timing",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        5-year survival",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Odds ratio [OR], 95% CI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        OS",
"       </td>",
"       <td class=\"subtitle3\">",
"        DFS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoadjuvant alone",
"       </td>",
"       <td>",
"        0.65 (0.51-0.84)",
"       </td>",
"       <td>",
"        0.63 (0.51-0.79)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concurrent alone",
"       </td>",
"       <td>",
"        0.72 (0.40-1.30)",
"       </td>",
"       <td>",
"        0.68 (0.46-0.99)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concurrent + adjuvant",
"       </td>",
"       <td>",
"        0.30 (0.16-0.55)",
"       </td>",
"       <td>",
"        0.30 (0.17-0.53)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adjuvant alone",
"       </td>",
"       <td>",
"        0.49 (0.18-1.31)",
"       </td>",
"       <td>",
"        0.60 (0.34-1.04)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All",
"       </td>",
"       <td>",
"        0.65 (0.51-0.83)",
"       </td>",
"       <td>",
"        0.59 (0.51-0.68)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CI: confidence interval; OS: overall survival; DFS: disease-free survival.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Thephamongkol, K, Zhouo, J, Browman, G, et al. Proc Am Soc Clin Oncol 2004; 23:491a (abstract 5522).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28459=[""].join("\n");
var outline_f27_50_28459=null;
var title_f27_50_28460="Antidotes pediatric poisoning B";
var content_f27_50_28460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended antidotes in pediatric poisonings (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antidote",
"       </td>",
"       <td class=\"subtitle1\">",
"        Poisoning indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Ethanol (10 percent)",
"       </td>",
"       <td>",
"        Methanol",
"       </td>",
"       <td rowspan=\"2\">",
"        Loading dose 10 mg/kg IV or PO, followed by maintenance dose 1 to 2 mL/kg per hour IV or PO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethylene glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fomepizole (4-methylpyrazole)",
"       </td>",
"       <td>",
"        Methanol",
"       </td>",
"       <td rowspan=\"2\">",
"        15 mg IV bolus, then 10 mg/kg IV every 12 hours for four doses; after these, increase dose back to 15 mg/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethylene glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Glucagon",
"       </td>",
"       <td>",
"        Beta-adrenergic antagonist",
"       </td>",
"       <td rowspan=\"2\">",
"        0.15 mg/kg IV bolus followed by 0.1 mg/kg per hour IV infusion titrated to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium channel blocker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylene blue",
"       </td>",
"       <td>",
"        Methemoglobinemia",
"       </td>",
"       <td>",
"        1 to 2 mg/kg slow IV infusion, repeat doses are common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Naloxone",
"       </td>",
"       <td>",
"        Acute opioid poisoning",
"       </td>",
"       <td>",
"        0.4 to 2 mg IV, titrated to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pralidoxime chloride (PAM)",
"       </td>",
"       <td>",
"        Organophosphate insecticide",
"       </td>",
"       <td>",
"        20 to 40 mg/kg slow IV infusion, followed by 5 to 10 mg/kg per hour continuous infusion or 20 mg/kg every four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyridoxine",
"       </td>",
"       <td>",
"        Isoniazid (INH)",
"       </td>",
"       <td>",
"        1 gm per gram ingested or empiric dosing 75 mg/kg IV bolus up to 5 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Sodium bicarbonate",
"       </td>",
"       <td>",
"        Tricyclic antidepressant",
"       </td>",
"       <td rowspan=\"2\">",
"        1 to 2 mEq/kg IV bolus, titrate repeat boluses to QRS duration do not exceed arterial pH 7.55)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylates",
"       </td>",
"       <td>",
"        150 mEq + 40 mEq KCl in 1L of D5W infused to maintain urine output at 1 to 2 mL/kg per hour and a urine pH approximately 7.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Dart, RC, Goldfrank, LR, Chyka, PA, Lotzer, D. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 2000; 36:126 and Clinical policy for the initial approach to patients presenting with acute toxic ingestion or dermal or inhalation exposure. Ann Emerg Med 1999; 33:735.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28460=[""].join("\n");
var outline_f27_50_28460=null;
var title_f27_50_28461="Opioid analgesics";
var content_f27_50_28461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Opioid analgesics used for the treatment of persistent pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Dose (mg) equianalgesic to morphine 10 mg IV",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Half-life",
"        <br/>",
"        (hours)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Duration",
"        <br/>",
"        (hours)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Oral",
"       </td>",
"       <td class=\"subtitle2\">",
"        IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morphine",
"       </td>",
"       <td>",
"        20 to 30*",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        2 to 4",
"       </td>",
"       <td>",
"        Standard for comparison.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morphine CR",
"       </td>",
"       <td>",
"        20 to 30",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        8 to 12",
"       </td>",
"       <td>",
"        Various formulations are not bioequivalent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morphine SR",
"       </td>",
"       <td>",
"        20 to 30",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxycodone",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        3 to 4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxycodone CR",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydromorphone",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        2 to 4",
"       </td>",
"       <td>",
"        Potency may change (ie, hydromorphone:morphine is 3:1 rather than 6.7:1 during prolonged use).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methadone",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12 to 190",
"       </td>",
"       <td>",
"        4 to 12",
"       </td>",
"       <td>",
"        Although a 1:1 ratio with morphine was observed in a single dose study, there is a change with chronic dosing. A large dose reduction (75 to 90 percent) is needed when switching to methadone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxymorphone",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        2 to 4",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxymorphone ER",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 to 3",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levorphanol",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        12 to 15",
"       </td>",
"       <td>",
"        4 to 6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fentanyl",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        0.1 (bolus)",
"       </td>",
"       <td>",
"        7 to 12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Can be administered as a continuous IV or SQ infusion.",
"        </p>",
"        <strong>",
"         Based upon clinical experience, 100 micrograms/hour fentanyl IV/SQ infusion is roughly equianalgesic to morphine 4 mg/hour IV/SQ, in patients receiving fentanyl chronically. For conversion from morphine to fentanyl in patients who have not received fentanyl chronically, 10 mg/hour IV/SQ morphine is roughly equianalgesic to 100 micrograms/hour IV/SQ fentanyl infusion.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fentanyl transdermal (sustained release patch)",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        17 (after removal)",
"       </td>",
"       <td>",
"        48 to 72",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Based upon clinical experience, to convert from IV morphine to initial transdermal fentanyl, 3 to 4 mg/hour IV morphine is roughly equianalgesic to 100 micrograms/hour transdermal fentanyl.",
"         </strong>",
"        </p>",
"        A ratio of oral morphine: transdermal fentanyl of 70:1 may also be used clinically.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Equianalgesic conversions serve only as a general guide to estimate opioid dose equivalents. For a review of multiple factors that must be considered for safely individualizing conversion of opioid analgesia, refer to the UpToDate topic on cancer pain management with opioids for optimizing analgesia.",
"    <div class=\"footnotes\">",
"     IM: intramuscular; IV: intravenous; SQ: subcutaneous.",
"     <br/>",
"     * Although the oral:IM morphine ratio was 6:1 in a single dose study, other observations indicate a ratio of 2-3:1 with repeated administration.",
"    </div>",
"    <div class=\"reference\">",
"     Source: Derby S, Chin J, Portenoy RK. Systemic opioid therapy for chronic cancer pain: practical guidelines for converting drugs and routes of administration. CNS Drugs 1998; 9:99. Additional data from: Swarm R, et al. Adult Cancer Pain. National Comprehensive Cancer Network Guidelines in Oncology version 2.2012 available at",
"     <a href=\"file://www.NCCN.org\" target=\"_blank\">",
"      www.NCCN.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28461=[""].join("\n");
var outline_f27_50_28461=null;
var title_f27_50_28462="Molecular targets in NSCLC";
var content_f27_50_28462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 601px\">",
"   <div class=\"ttl\">",
"    Molecular targets in non-small cell lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 581px; height: 362px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathways for molecularly targeted therapy in non-small cell lung cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original, courtesy of Dr. Joel Neal.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_50_28462=[""].join("\n");
var outline_f27_50_28462=null;
var title_f27_50_28463="Contents: Antenatal care";
var content_f27_50_28463=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Antenatal care",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Antenatal care",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adaptations to pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/61/35798\">",
"           Androgen production and metabolism in normal pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/37/26198\">",
"           Approach to liver disease occurring during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/33/2584\">",
"           Calcium physiology in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21703\">",
"           Hematologic changes in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/47/14073\">",
"           Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/22/36201\">",
"           Immunology of the maternal-fetal interface",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/40/20105\">",
"           Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/61/13274\">",
"           Maternal endocrine and metabolic adaptation to pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/60/9160\">",
"           Maternal gastrointestinal tract adaptation to pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/1/2074\">",
"           Musculoskeletal changes and pain during pregnancy and postpartum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/7/14454\">",
"           Normal reference ranges for laboratory values in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16186\">",
"           Overview of thyroid disease in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24072\">",
"           Renal and urinary tract physiology in normal pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/37/32340\">",
"           Respiratory tract changes during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/62/35816\">",
"           The skin, hair, nails, and mucous membranes during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/37/20056\">",
"           Work and pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnosis of pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/48/44808\">",
"           Clinical manifestations and diagnosis of early pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fetal assessment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/11/2232\">",
"           Antepartum fetal heart rate assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/52/31558\">",
"           Assessment of amniotic fluid volume",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/58/42919\">",
"           Assessment of fetal lung maturity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/41/5783\">",
"           Diagnosis and outcome of first trimester growth delay",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/30/10728\">",
"           Doppler ultrasound of the umbilical artery for fetal surveillance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/37/15959\">",
"           Evaluation of decreased fetal movements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/7/23674\">",
"           Intrapartum fetal heart rate assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/13/25815\">",
"           Nuchal cords",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30121\">",
"           Overview of fetal assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/47/34553\">",
"           Prenatal assessment of gestational age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/1/25\">",
"           Prenatal sonographic assessment of fetal weight",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/35/43576\">",
"           Routine prenatal ultrasonography as a screening tool",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/41/11928\">",
"           The fetal biophysical profile",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36824\">",
"           Ultrasound examination in obstetrics and gynecology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/56/14217\">",
"           Venous Doppler for fetal assessment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Immunization",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/53/32602\">",
"           Immunizations during pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Newborn issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/46/41705\">",
"           Neonatal circumcision: Risks and benefits",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prenatal care",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/29/4568\">",
"           Anatomical and physiological changes of pregnancy and exercise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/57/19354\">",
"           Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/62/22503\">",
"           Cystic fibrosis: Prenatal genetic screening",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/7/31865\">",
"           Effect of advanced age on fertility and pregnancy in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/54/30567\">",
"           Effect of advanced paternal age on fertility and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27945\">",
"           Fertility and pregnancy after bariatric surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/13/7386\">",
"           Genetic and environmental causes of birth defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/49/11030\">",
"           Group prenatal care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/1/42010\">",
"           Initial prenatal assessment and patient education",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/48/35590\">",
"           Management of infertility and pregnancy in women of advanced age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/44/28362\">",
"           Nutrition in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/9/17556\">",
"           Obstetrical issues in grand multiparity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/27/22969\">",
"           Overview of prenatal screening and diagnosis of Down syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/25/16794\">",
"           Preconception evaluation and counseling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/31/10744\">",
"           Pregnancy in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/29/24023\">",
"           Pregnancy in homeless women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/48/44807\">",
"           Prenatal care (after initial prenatal assessment)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/39/632\">",
"           Prenatal care for incarcerated women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/35/25145\">",
"           Prenatal screening and diagnosis of neural tube defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/24/12681\">",
"           Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/30/7657\">",
"           Recommendations for exercise during pregnancy and the postpartum period",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/31/33273\">",
"           Risks and benefits of fish consumption and fish oil supplements during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/35/43576\">",
"           Routine prenatal ultrasonography as a screening tool",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/35/20026\">",
"           The effects of caffeine on reproductive outcomes in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/11/29882\">",
"           The impact of obesity on fertility and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/33/21017\">",
"           Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36824\">",
"           Ultrasound examination in obstetrics and gynecology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/54/19304\">",
"           Weight gain and loss in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prenatal diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27592\">",
"           Basic principles and safety of diagnostic ultrasound in obstetrics and gynecology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/0/31751\">",
"           Basic principles of genetic counseling for the obstetrical provider",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/32/28169\">",
"           Chorionic villus sampling: Risks, complications, and techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/0/23562\">",
"           Congenital cytogenetic abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/62/22503\">",
"           Cystic fibrosis: Prenatal genetic screening",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/11/16570\">",
"           Diagnostic amniocentesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11768\">",
"           Fetal blood sampling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/20/36166\">",
"           Fetal echogenic bowel",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/22/7529\">",
"           First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/50/2857\">",
"           First trimester cystic hygroma and increased nuchal translucency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/61/5081\">",
"           Folic acid for prevention of neural tube defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/39/27257\">",
"           Laboratory issues related to maternal serum screening for Down syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/52/42824\">",
"           Overview of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/27/22969\">",
"           Overview of prenatal screening and diagnosis of Down syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/2/29736\">",
"           Parentage testing using DNA",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/57/18329\">",
"           Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27210\">",
"           Prenatal diagnosis and obstetrical management of umbilical cord abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/44/2762\">",
"           Prenatal diagnosis of CNS anomalies other than neural tube defects and ventriculomegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/26/1448\">",
"           Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/54/23399\">",
"           Prenatal screening and diagnosis for fragile X syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/35/25145\">",
"           Prenatal screening and diagnosis of neural tube defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/24/12681\">",
"           Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34247\">",
"           Prenatal sonographic diagnosis of fetal abdominal wall defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/24999\">",
"           Prenatal testing for the hemoglobinopathies and thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/29/1493\">",
"           Second trimester maternal serum screening for Down syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/14/8423\">",
"           Single umbilical artery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/41/22170\">",
"           Sonographic findings associated with fetal aneuploidy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/46/35560\">",
"           Ultrasound diagnosis of neural tube defects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/2/7208\">",
"           Use of array comparative genomic hybridization (aCGH) in obstetrics",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-AC901B1C2D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_50_28463=[""].join("\n");
var outline_f27_50_28463=null;
